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Short interfering RNAs (siRNAs) are biomolecules used for post-transcriptional gene 
regulation, and therefore hold promise as a future therapeutic by silencing gene 
expression of overexpressed deleterious genes. Chemically modifying the RNA 
structure is used to overcome the inherent limitations of the RNA structure. This 
project investigated the ability of a library of chemically modified siRNAs to target, 
in vitro, the therapeutically relevant oncogene, BCL2, by combining 2'-ribose sugar 
modifications with a novel triazole-linked backbone modification, previously 
described by our group. Solid support phosphoramidite chemistry was used to 
incorporate chemical modifications at various positions within anti-BCL2 siRNAs. In 
vitro effects were evaluated through qPCR, cell viability, nuclease stability, and an 
immunological ELISA assay. Our results indicate that these unique modifications are 
well tolerated within RNAi and show enhanced activity and stability over natural 
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Chapter 1: Literature Review 
1.1 The “New” Central Dogma of Molecular Biology: RNAi 
DNA into RNA into protein; the central dogma of molecular biology. This term was first 
coined in 1958 by the co-discoverer of DNA, Dr. Francis Crick, and was used to describe 
the flow of genetic information through biological systems (Crick, 1970). DNA serves as 
the storage of genetic information and provides the instructions for every function within 
the cell. RNA acts as an intermediate messenger, carrying the information of DNA to be 
translated into proteins. Proteins are the macromolecules which perform many of the 
biochemical reactions within the cell. The general idea of the central dogma still holds 
true today but our understanding has become somewhat more nuanced and less restrictive 
than DNA-RNA-Protein. RNA is a versatile biological macromolecule which seems to 
violate the classical understanding of the central dogma. RNA can be reverse transcribed 
into DNA (Baltimore, 1970; Temin & Mizutani, 1970), replicated into RNA (Koonin, et 
al., 1989) and can either up or down-regulate RNA and DNA expression (Li, et al., 2006; 
Hannon, 2002). The role of RNA within the central dogma of molecular biology is now 
more than a simple messenger, as it plays a key role in gene regulation.  
Understanding RNA’s role within the cell is a quickly growing area of research since the 
discovery of RNA interference (RNAi). The first hint of RNA interference was reported 
by Napoli, Lemieux and Jorgensen (1990). The aim of the study was to overexpress 
chalcone synthase gene (CHS) in petunias. This was accomplished through the 
introduction of the CHS gene using copy DNA (cDNA) via Agrobacterium tumefaciens 
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transformation. However, by introducing the gene they found the messenger RNA 
(mRNA) levels of the corresponding gene to be 50-fold lower than expected, and 
postulated this down-regulation was caused by a yet unknown mechanism. This 
unexpected result arose again in 1992 when researchers discovered mRNA depletion 
when the cDNA of a homologous mRNA sequences was introduced into the plant host 
(Romano & Macino, 1992). Soon, this unexplained phenomenon was observed in animals 
when Guo and Kemphues (1995) incubated C. elegans with sense and anti-sense RNA 
oligonucleotides corresponding to an endogenous mRNA. At the time, anti-sense mRNA 
was a known phenomenon, but the unexpected result was when the sense RNA, which 
could not hybridize with the endogenous mRNA, was still degraded. These findings 
overturned the conventional wisdom of the time by going against the central dogma. Fire 
and Mello (1998) followed up these studies by investigating the exact causes of this 
apparent RNA suppression, trying to tease apart the factors affecting this phenomenon. In 
their study they found that single stranded RNA (ssRNA) alone were not able to affect 
mRNA levels; but when ssRNA of the sense strand was injected into the animals, 
followed by the antisense strand (or the other way around) mRNA levels were diminished 
(hybridization of the ssRNA to form dsRNA occurred in vivo). This observation 
suggested that dsRNA, not ssRNA, was the trigger of this biological process (Fire, et al., 
1998). The impact of this paper was enormous, sparking a new field of research and 
leading to a Nobel Prize for Fire and Mello in 2006 (less than a decade after their initial 
publication).   
The next major step in RNAi was the elucidation of the exact trigger. Hamilton and 
Baulcombe (1999) postulated that at some point, the dsRNA must dissociate the sense 
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strand and use the anti-sense strand to bind the targeted mRNA. Through investigation of 
mRNA knock-down induced by viruses in plants models, they detected 25 nucleotide 
long antisense RNAs present, which they postulated are derived from a dsRNA source, 
causing the silencing (Hamilton & Baulcombe, 1999). The definitive proof of small 
dsRNA causing RNA interference was determined by Elbashir and collogues (2001). By 
incubating Drosophila cell extracts with dsRNA of various nucleotide lengths they 
demonstrated that synthetic 21- and 22-nt dsRNAs, with 3′ overhanging ends, act as the 
trigger for sequence-specific mRNA degradation. This served as the basis in which 
siRNAs are still designed, with a few minor refinements. 
Concurrently, while the exact details of siRNAs were being investigated the RNAi 
pathway was discovered in a variety of eukaryotic taxa, including: animals, fungi, plants, 
and protozoa. Based on phylogenetic analysis, the most recent common ancestor of all 
eukaryotes most likely possessed an early RNAi pathway, indicating that RNAi is an 
ancient and conserved biological mechanism (Cerutti & Casas-Mollano, 2006). This lead 
to the understanding that RNAi is a broad biological pathway endogenously conserved 
within most, if not all, eukaryotes and this pathway included much more than the small 
interfering RNA.  
1.2 RNAi Pathway 
RNAi is an endogenous pathway which starts in the genome of an organism. Within the 
genome of eukaryotic organisms there are genes whose sole purpose is to be transcribed 
into non-coding RNA which only serve to regulate mRNA within the cell. These RNA 
are responsible for development, response to stress, and response to viral infections. As 
much as 5% of the human genome serves the sole purpose of encoding and producing 
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over 1000 of these regulatory RNAs; these regulatory RNAs govern the expression of 
over 30% of all genes (MacFarlane & Murphy, 2010). It has even been recently stated 
that the complexity of an organism is directly correlated to the number of regulatory 
RNAs present within the genome (Berezikov, 2011).  
RNAi begins in the nucleus; a long RNA is transcribed and is known as the primary 
micro-interfering RNA transcript (pri-miRNA). Pri-miRNAs are typically over 1000 
nucleotides in length and contain several secondary structures throughout. This pri-
miRNA is then processed by a complex of proteins known as the microprocessor unit. 
The microprocessor unit is comprised of two key proteins, Dorsha and Pasha. Pasha is a 
dsRNA binding protein and Dorsha is a ribonuclease class III family enzyme with 
endonuclease capabilities. Dorsha cleaves the pri-miRNA into the precursor miRNA (pre-
miRNA). The resulting pre-miRNA is typically 65-70 nucleotides in length and contains 
a distinctive double stranded stem-loop secondary structure and is immediately 
transported out of the nucleus and into the cytoplasm through a nuclear pore with the aid 
of transport facilitators Exprotin-5 and RanGTP (Lund & Dahlberg, 2006).  
Once in the cytoplasm, the pre-miRNA is taken up by a protein known as Dicer, which 
cleaves the pre-miRNA into a fully mature micro interfering RNA (miRNA). It is at this 
point in the RNAi pathway which exogenous siRNAs and endogenous miRNAs 
converge. The resultant RNA is a duplex roughly 21-25 nucleotides long, with a 2 
nucleotide overhang at each 3’-end of the duplex and a phosphate group at each 5’-end of 
the duplex. The duplex itself has an A-type helical secondary structure (Chiu & Rana, 
2002; Schwarz, et al., 2003).  
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The next steps of the RNAi pathway are still an area of contention, but the leading theory 
is that Dicer recruits a double stranded RNA binding protein (TRBP) and together 
associate with argonaute (Ago) to form the RISC-loading complex (RLC). The dsRNA is 
then loaded into Ago, with one of the the 3’-ends associating with the PAZ domain and 
the 5’-phosphate end associating with the MID domain. The loading step is concurrent 
with strand selection, where one strand dissociates and the other is retained by Ago 
(Fabian & Sonenberg, 2010). The retained strand is the anti-sense, which is 
complementary to the mRNA target (this strand is known as the guide strand). The 
discarded strand is the equivalent sense strand to the mRNA target and is known as the 
passenger strand.  
The basis for strand selection is based on the thermodynamics of the duplex sequence, the 
least thermodynamically stable 5’-end of the dsRNA is incorporated into Ago and the 
other strand is dissociated. This phenomenon is called the thermodynamic asymmetry 
principal (Kawamata & Tomari, 2010). Once the RNA is loaded into Ago, the protein 
complex is considered active and is known as the RNA-induced silencing complex 
(RISC).  
RISC then undergoes cellular surveillance, scanning for a complementary sequence to the 
guide strand. Nucleotides 2-8 (counting from the 5’-end) of the guide strand initiate 
binding to the complementary sequence this is known as the seed region (Jackson, et al., 
2006) (Ui-Tei, et al., 2008). This seed region does not need to have exact molecular 
complementarity with the target mRNA, but the extent of base-pairing does affect the 
subsequent silencing steps. If there is perfect complementation, and Ago2 is utilized over 
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the other Ago proteins, RISC undergoes canonical RNAi. If there are mismatches within 
the seed region, RISC undergoes non-canonical RNAi (Fabian & Sonenberg, 2010).   
Canonical RNAi involves Ago2 and perfect seed sequence complementarity and is 
considered the “main” pathway of silencing. When RISC finds the complement mRNA 
sequence Ago2 will cleave the target mRNA sequence through its endoribonuclease III 
activity, cleaving the phosphodiester bond through hydrolysis resulting in 3′-hydroxyl 
and 5′-phosphate terminus products (Martinez & Tuschl, 2004). The RISC can continue 
its gene suppression by binding to and degrading any complementary mRNA sequences it 
encounters (Figure 1). 
 




Non-canonical RNAi involves any of the other Ago proteins. There are four unique 
argonaute proteins found within humans, Ago1 through 4 (Doi, et al., 2003). They share 
common amino acid sequences yet only Ago2 has cleavage activity (Meister, et al., 
2004). The other three Ago proteins do not contain a conserved catalytic tetrad within the 
PIWI domain of Ago2, which is the required for its slicing activity (Faehnle, et al., 2013). 
The RISC complex will bind its mRNA target and then associate with several other 
proteins and localize in processing bodies (P-bodies) within the cytoplasm. The P-bodies 
repress translation and enhance mRNA turnover via de-adenylation and de-capping 
proteins (Braun, et al., 2013). The details of the exact mechanisms, the protein players, 
protein interaction, molecular timing, and the importance of P-bodies has yet to be 
determined (Wilson & Doudna, 2013).  
This molecular pathway is not only essential for the development and health of all 
eukaryotic organisms but through the use of exogenous siRNAs, this pathways has 
opened up doors which were once thought impossible in areas of biological research and 
potential therapeutics.  
1.3 Application of siRNAs 
The discovery of RNAi and the development of functional synthetic siRNAs has caused a 
revolution in basic biological research. SiRNAs can be used as a general tool for 
eukaryotic gene function studies, and have quickly become a popular tool for researchers 
across the globe. Researchers have been quick to adopt RNAi tools because of their 
relative ease to study gene function within eukaryotic organisms. A benefit of using 
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RNAi is its transient gene knockdown in adult mammalian organisms. Because of this 
transient gene knockdown, siRNAs can overcome the limitations that classical 
approaches cannot accomplish, due to embryonic lethal mutations which can occur 
through classical genetics (Brummelkamp & Bernards, 2003). SiRNAs can be used to test 
hypotheses of gene function, for validation of targets for potential therapeutics, for the 
analysis of protein pathways, to investigate gene redundancy, to generate libraries of 
siRNAs to perform functional screening of genes, and finally as a possible therapeutic. 
SiRNAs can be used to validate gene function and investigate protein pathways within 
complex eukaryotic organisms. Researchers can make predictions of mammalian gene 
function through the use of comparative homology searches with genes whose functions 
are known in model organisms. In many cases, testing the accuracy of these predictions 
can be accomplished using siRNAs. One of the earliest applications of siRNAs in the 
study of gene function was by Kennerdell and Cathew (1998). Shortly after the discovery 
of RNAi they used dsRNA to study the role of frizzled and frizzled 2 within the wingless 
pathway in Drosophila. Within a couple years, the utility of siRNA as a tool was 
expanded further by Burns, et al. (2004). In their study, they generated a library of 
siRNAs by constructing a set of retroviral vectors encoding 23,742 distinct siRNAs, 
which target 7,914 different human genes. The library was then used to discover five new 
genes which were key modulators of p53-dependent cellular proliferation arrest. This 
study clearly demonstrated the ability of RNAi for functional screens for complex 
eukaryotic organisms.  
SiRNAs can also be used to validate targets for potential therapeutics. One of the first 
examples of using siRNA to validate therapeutic targets was by Li, et al. (2003). They 
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used siRNAs to reduce cyclin E expression in hepatocellular carcinoma (HCC) cells and, 
as expected, the cyclin E siRNA promoted apoptosis of HCC cells and blocked cellular 
proliferation in vitro. In in vivo mice models, cyclin E siRNAs inhibited HCC tumor 
growth in nude mice validating the in vitro results and highlighting the potential for 
creating drugs targeting cyclin E. This had lead into siRNAs being used as a viable 
therapeutic. 
 SiRNAs are able to be designed based solely on the mRNA sequence of the desired 
target. Therefore, any biological target can potentially become druggable through the use 
of siRNAs. This provides a distinct advantage over small molecule drug design, which is 
time consuming, vastly expensive, and a fortuitous process (Hughes, et al., 2011). It has 
also been stated that only 10-15% of all proteins are considered druggable by small 
molecules due to the complex structure and interactions of proteins in vivo (Griffith, et 
al., 2013). As such, there is great hope in siRNAs becoming a viable therapeutic option 
because of their distinct advantage over traditional small molecule drug design.  
1.4 Limitations of siRNAs 
Although siRNA based therapeutics seems like an ideal way to manage and treat disease, 
there are several important therapeutic limitations associated with siRNAs. The most 
glaring limitations include off-target effects/undesired strand selection, innate immune 
response to foreign nucleic acids, serum nuclease stability, and suitable delivery methods.  




Although siRNAs are tailored to match the sequence of the target mRNA, there are still 
off-target effects associated with siRNA administration. Off-target effects are when the 
siRNA knocks down an unintended mRNA sequence, which usually results in an 
undesired phenotypic effect. When researches design siRNAs sequence homology is 
considered when picking the target sequence. Sequence homology searches are 
performed to try to eliminate overt cross-reactivity. Yet, sequence homology alone is not 
able to fully predict the actual risk of off-target effects for the siRNAs. There are two 
major factors for unexpected off-target effects, one being the nature of the seed region of 
the siRNA and the other being improper strand selection by RISC.   
The seed region of the siRNA is responsible for finding and complementing the target 
mRNA and is only 7 nucleotides in length (nucleotides 2–8 at the 5′-end of the guide 
strand). As such, the overall identity of the siRNA or the target mRNA makes little to no 
contribution to determining whether the expression of a particular gene will be affected. 
Instead, off-targeting is associated with the presence of one or more perfect 3'-
untranslated region (UTR) matches with the seed region of the siRNA (Birmingham, et 
al., 2006). Therefore, when designing an siRNA, it is best to design based on the seed 
region complementation to the UTR of the target mRNA sequence to help mitigate 
unwanted off-target effects. The other major reason for unintended off-target effects is 
improper strand selection by RISC. Strand selection is based on the thermodynamic 
asymmetry rule, which states that the least thermodynamically stable 5’-end of the 
dsRNA is incorporated into Ago and the other strand is dissociated (Kawamata & 
Tomari, 2010). Therefore the sequence of the siRNA affects the likelihood of proper 
strand selection; an ideal sequence would contain low GC content around the 5’-end and 
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high GC content around the 3’-end of the antisense strand. If the siRNA duplex does not 
follow the asymmetry principal, the improper strand is likely to be incorporated into 
RISC, which can lead to knockdown of an unintended mRNA target. Taken together, the 
siRNA sequence must be carefully designed to try to avoid off-target effects. 
Another major hurdle for siRNA therapeutics is host recognition and immune activation. 
SiRNA duplexes can activate the innate immune response in humans resulting in the 
secretion of high levels of inflammatory cytokines such as tumor necrosis factor alpha 
(TNF-α), interleukin-6 (IL-6), and interferon-alpha (IFN-α) (Hornung, et al., 2005; Judge 
et al., 2005). The human immune system has evolved sophisticated innate defences 
against foreign nucleic acids (Krieg, et al., 1995). The innate immune response to siRNAs 
is either through a toll-like receptor (TLR)-mediated response or a non-TLR mediated 
response (Robbins, et al., 2009).  
There are thirteen known toll-like receptors in humans, three of which are capable of 
sensing RNAs (TLR 3, 7 and 8). These TLRs are located intracellularly and normally 
respond to nucleic acids by directly binding the RNA/DNA of viral invaders or by the 
nucleic acids from invading pathogens as they are released from lysosomes. TLR 3 is not 
only found intracellularly but it is also located on the outer membrane and can detect 
foreign nucleic acids outside of the cell (Kawai & Akira, 2011; Ozinsky, et al., 2000). 
TLR 7 and TLR 8 indiscriminately recognize dsRNA and ssRNA, simply recognizing the 
phosphate ribose backbone and uracil bases of ribonucleic acids (Diebold, et al., 2006). 
When TLR 7 or TLR 8 are stimulated by RNA they associate with the adaptor protein 
MyD88, forming a signaling complex (Takeda & Akira, 2005). The signal transduction 
leads to the nuclear translocation of NF-κB, causing the activation of transcription factors 
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responsible for up-regulating the expression of IFN-α and TNF-α, primary pro-
inflammatory cytokines (Akira & Takeda, 2004; Kawai & Akira, 2006). TLR 3 is 
somewhat unrelated to TLR 7 or TLR 8 as it is genetically distinct, is expressed on the 
cellular surface as well as intracellularly, and activates a distinct signaling pathway. TLR 
3 does not associate with the adaptor protein MyD88 but rather the TRIF adaptor protein, 
which eventually triggers a positive feedback mechanism starting with the secretion of 
IFN-α and β which then signal back to the cell causing the up-regulation other IFN-
inducible genes, leading to the production of additional IFN-α (Kawai & Akira, 2006). 
The activated TLR 3/TRIF complex also triggers a signal cascade which leads to the 
activation of NF-κB, ATF, and c-Jun transcription factors which in turn induce the 
secretion of pro-inflammatory cytokines such as IL-6 and TNF-α (Kawai & Akira, 2006).  
In addition to TLRs there are non-TLRs within the cytoplasm which trigger the innate 
immune response. The two major proteins are dsRNA-binding protein kinase (PKR) and 
RIG-1. PKR is a protein found within the cytoplasm which has a N-term dsRNA binding 
domain and a C-term kinase domain. When it binds dsRNAs, the PKRs will dimerize and 
autophosphorylate. This event starts a signal transduction pathway which leads to NF-κB 
activation, which in turn up-regulates pro-inflammatory cytokines (Feng, et al., 1992; 
Balachandran, et al., 2000; García, et al., 2007). The other major non-TLR protein is 
retinoic acid-inducible gene (RIG-1). RIG-1 is a cytoplasmic RNA helicase which acts as 
a sensor of viral RNA via binding and activation by either single-stranded or double-
stranded RNA (Marques, et al., 2006; Pichlmair, et al., 2006). When RIG-1 binds to 
dsRNA, it triggers a cascade which leads to the activation of NF-κB leading to the 
production of primary interferons (Kawai, et al., 2005).  
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Overall, the presence of dsRNA, including siRNAs, causes the activation of the innate 
immune system, leading to the secretion of pro-inflammatory cytokines. These pro-
inflammatory cytokines cause traditional inflammation symptoms: pain, increased body 
temperature (fever), redness, and swelling. The presence of siRNA could potentially 
trigger a runaway positive feedback loop causing systemic inflammatory response 
syndrome. Systemic inflammatory response causes whole body inflammation, leading to 
organ malfunction and damage and can be life threatening (Bone, et al., 1992; Teijaro, et 
al., 2014).  
Because of the potential for severe immune response to RNA, siRNA therapeutics must 
proceed with the utmost caution before human trials are conducted. The precedent set by 
the TeGenero disaster in 2006 has made therapeutic companies more cautious when 
proceeding human trials of novel bio-pharmaceuticals. The TeGenero disaster involved 
an experimental antibody, which showed no immune stimulation in pre-clinical trials, 
administered to six healthy male volunteers at very low doses. Within an hour, all six 
displayed systemic inflammatory response characterized by a rapid induction of 
proinflammatory cytokines showing symptoms of: headache, nausea, diarrhea, erythema, 
vasodilatation, and hypotension. Within 24 hours, all six patients became critically ill, 
experiencing renal failure, widespread activation of the clotting cascade, complete 
depletion of lymphocytes/monocytes and organ failure (Suntharalingam, et al., 2006).  
Due to the unforeseen immunological outcome of the TeGenero disaster siRNA 




Beyond the biological consequences of off-target effects and innate immune activation 
siRNAs also face the challenge of being degraded by nuclease enzymes. Once siRNAs 
are administered in an in vivo system, they are immediately targeted by serum endo and 
exoribonucleases, specifically ribonuclease-A (Haupenthal, et al., 2006; Turner, et al., 
2007). The 2’-OH of the ribose sugar is essential for catalytic activity of ribonucleases as 
the 2’-OH then nucleophilically attacks the phosphate, resulting in a 2’, 3’-cyclic 
phosphodiester, where the 5’-nucleotide leaves as the truncated product (Raines, 1998). 
In a comprehensive analysis by Hong, et al. (2010), the nuclease stability of 125 unique 
and unmodified dsRNAs was assessed in human and fetal calf serum. Mapping of the 
cleavage events occurring in serum treatment revealed two areas of vulnerability, UA/UA 
and CA/UG sites, and further solidified RNase A’s role in siRNA degradation. SiRNAs 
propensity of being readily degraded in the presence of ribonucleases presents a major 
limitation that must be overcome to develop a potential siRNA therapeutic. 
Nucleases are not the only challenge to siRNAs after administration; biodistribution and 
delivery to target cells are other challenges facing siRNA therapeutics. Administered 
siRNAs have poor tissue-targeting, a low propensity to target specific cells, and low 
cellular permeability. Systematic studies of the pharmacokinetic properties of 
oligonucleotides and siRNAs in vivo have shown that, once administered, siRNAs tend to 
accumulate in the kidneys and the liver but are noticeably absent in the central nervous 
system (Juliano, et al., 1999). Further investigation, using in vivo animal systems have 
shown that less than 1% of the administered siRNA will make it to the targeted tissues 
(Mescalchin, et al., 2007), demonstrating that siRNAs are not effective at reaching target 
tissues. Another problem is, due to siRNAs large molecular weight (~13 kDa) and 
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polyanionic nature (~40 negative phosphate charges), naked siRNAs do not effectively 
cross the cell membrane on their own. As such, siRNA therapeutics will not be effective 
therapeutics until these delivery and biodistribution issues can be overcome (Juliano, et 
al., 2009).   
1.5 Chemical Modifications of siRNAs to Overcome Therapeutic Barriers 
While these therapeutic challenges facing siRNA therapeutics seem daunting and more 
than enough to rule out siRNA as a future therapeutic, the challenges, however, are not 
insurmountable and the answer lies within the chemical structure of RNA. By chemically 
modifying the native structure of RNA, many of the therapeutic limitations can be 
diminished, making siRNA therapy a viable therapeutic option. Changing the chemical 
structure of oligonucleotides to overcome practical therapeutic challenges has been 
widely studied and well established for many years. In the 1970s, it was discovered that 
synthetic oligonucleotides, which were complementary to a mRNA sequence, could 
arrest the translation process in vivo (Stephenson & Zamecnik, 1978; Zamecnik & 
Stephenson, 1978). Since their discovery, anti-sense oligonucleotides (ASOs) have been 
thoroughly investigated with the hopes of developing a therapeutic. Recently, this work 
has led to two FDA approved oligonucleotide therapeutics: Fomivirsen and Mipomersen 
(Athyros, et al., 2008). ASOs successful approval has highlighted the need for chemical 
modification to be successful and gain FDA approval, as both commercially available 
oligonucleotides contain a plethora of modifications throughout their structure (Geary, et 
al., 2002; Hair, et al., 2013). As such, much of what has been learned from ASOs can be 
applied to siRNA design to help overcome therapeutic limitations associated with 
oligonucleotide based therapies.  
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Many chemical modifications are rationally designed, allowing for specific alterations of 
many of the inherent properties of native oligonucleotides and thus changing their 
biological application and potency. These modifications can help minimize off-target 
effects, modulate duplex structure/conformation, incur nuclease resistance, and reduce 
immunostimulatory properties.  
Chemical modifications can be grouped into three broad categories: (1) internucleotide 
backbone modifications (Deleavey & Damha, 2012), (2) sugar modifications (Prakash, 
2011), and (3) nucleobase modifications (Herdewijn, 2000). Each group has unique 
advantages and disadvantages when used in oligonucleotide design and varying effects in 
terms of overcoming the therapeutic limitations.  
Chemical modification of the nucleobase is a modification employed in oligonucleotide 
design to alter thermal stability, reduce immune activation, and help limit off-target 
effects. Nucleobase modifications also include incorporation of novel fluorophores that 
can be used for studying nucleic acid-containing systems (Wilhelmsson, 2010). Figure 2 




Figure 2 – Chemical structures of select nucleobase modifications.  
 
 Most nucleobase modifications alter duplex thermal stability, sugar conformation, and 
hydrogen-bonding properties of the duplex, all of which modulate the thermodynamics of 
duplex formation. These modifications can either maintain classical hydrogen bonding 
through nitrogen and oxygen heteroatoms or lack classical hydrogen bond donating 
groups completely while still maintaining base pair complementation (Peacock, et al., 
2011). Due to the thermodynamic modulation that base modifications incur upon duplex 
formation, they can be incorporated into siRNAs to tailor sequences to better meet the 
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thermodynamic asymmetry principal, increasing potency and helping to reduce 
inappropriate strand selection (Addepalli, et al., 2010).  
Sugar modifications are the most common chemical modifications used in 
oligonucleotide design and as such are the best understood and studied chemical 
modifications. This is because the effects of the sugar modification can be understood in 
terms of nucleotide sugar puckering preferences and thus the biological significance can 
be inferred (Deleavey & Damha, 2012). Sugar puckering has a large effect upon the 
thermodynamics of the duplex which in turn affects secondary structure, binding affinity 
toward complementary strands and enzyme interactions. Most modified ribose sugar 
derivatives either adopt conformations characterized as either RNA-like north 
conformation (C3’-endo, C2’-exo), or DNA-like south conformation (C2’-endo, C3’-exo) 
(Figure 3) (Altona & Sundaralingam, 1972; Blackburn, et al., 2006).  
 
Figure 3 – Ribose sugar puckering conformations of DNA and RNA. 
 
In B-form, dsDNA sugars adopt the ‘‘south’’ puckering, whereas in A-form dsRNA 
sugars prefer the ‘‘north’’ conformation. The cellular enzymes involved in the RNAi 
pathway can only tolerate duplexes in the A-form conformation. Thus, it is important to 
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have chemical modifications which help stabilize the duplex in A-form helical 
conformations. There are a vast array of sugar modifications compatible with 
oligonucleotide design, which can have either stabilizing or destabilizing effects upon the 
duplex (Figure 4). 
 




Among the various sugar modifications the two modifications which have garnered the 
most attention, and are the most used modifications in oligonucleotide design: the 2’-O-
Methyl (2’-O-Me) and the 2’-Fluoro (2’-F) modifications (Prakash, et al., 2005). These 
modifications are well tolerated within the RNAi pathway and have shown to increase 
potency of gene knockdown (Wu, et al., 2014). They have a high amount of resistance to 
nuclease degradation and thus, higher blood serum half-life (Volkov, et al., 2009; 
Chounga, et al., 2006). These modifications also incur thermodynamic stabilization, 
helping stabilize the A-form RNA helix (Majlessi, et al., 1998). Because of their 
stabilizing nature, they can be placed logically within the siRNA duplex to help aid in 
strand selection by following the thermodynamic asymmetry principal (Manoharan, 
1999; Kawamata & Tomari, 2010). Among these benefits, these 2’-modifications also 
show innate immune evasion in vitro and in vivo. Native siRNAs are strong activators of 
the immune response, yet small amounts of 2’-modification can diminish immune 
response completely (Judge, et al., 2006). On-top of all these beneficial properties of 2’-
O-Me and 2’-F modifications, they can also be combined with other modifications to 
further enhance these therapeutic properties, improving potency, immune evasion, 
nuclease stability, and overall tolerance within the RNAi pathway (Wu, et al., 2014).    
Beyond sugar modifications, another common chemical modification that has been 
successfully incorporated into siRNAs is internucleotide backbone modifications. There 
is a significant variety of backbone modifications, ranging from subtle one atom changes 
to a complete redesign of the molecular architecture (Figure 5). Two of the more common 
backbone modifications include, phosphorothioate nucleic acids (PS RNA) and 
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boranophosphate nucleic acids (BO RNA); other backbone modifications are not as 
widely used.  
 




The phosphorothioate (PS) linkage, where sulfur substitutes one of the non-bridging 
phosphate oxygen (Eckstein, 2002), is one of the most popular chemical modifications 
used for siRNA design. The PS linkage shows substantial resistance to nucleases and is 
widely used in siRNA design and has some affinity for serum albumin helping the 
biodistribution and increasing circulation time in vivo (Watanabe, et al., 2006; Geary, et 
al., 2001). PS-modified AONs can also be taken up by cells without the use of 
transfection or electroporation (Stein, et al., 2010). However, this modification is not 
without its problems, as PS linkages have shown to have toxicity issues and diminished 
siRNA activity when compared to native siRNAs (Bennett & Swayze, 2010).  
Another common modification of the phosphate backbone is the introduction of a boron 
atom in place of one of the non-bridging oxygen atoms to create a boron-phosphorous 
linkage, boranophosphate (BO). This modification has shown improved gene silencing 
activity at lower concentrations relative to either PS siRNAs or native siRNAs and 
enhanced resistance to degradation by nucleases, but they are limited in their uses 
because of suboptimal synthetic methods (Hall, et al., 2004).  
Peptide nucleic acids (PNAs) are another widely studied backbone modification. PNAs 
have a neutral backbone oligonucleotide mimic, in which the pyrimidine and purine bases 
are connected through a methylene carbonyl linker to an amino ethyl glycine backbone 
and are able to form stable duplexes with complementary base pairing (Egholm, et al., 
1993). They also exhibit significant nuclease and protease resistance (Demidov, et al., 
1994). Since the discovery of PNAs, a wide variety of PNA analogs have been developed 
and studied for oligonucleotide and siRNA applications (Pensato, et al., 2007). Their 
success is somewhat limited by their  low solubility in aqueous environment and their 
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poor cellular uptake, thus further modification of the PNA backbone is needed to perfect 
a therapeutically viable chemical modification (Pellestor & Paulasova, 2004).  
1.6 Triazole-Linked Backbone Modification 
Despite all the success of the various chemical modifications there is still no universal 
chemical modification used to overcome all therapeutic limitations. Thus, there is still a 
need to develop novel chemical modifications. The triazole functionality has been used 
by researchers to develop novel RNA backbone modifications through the use of click 
chemistry. Click chemistry was pioneered by Sharpless in 2001 (the Cu(I)-catalyzed 
adaptation of Huisgen’s 1,3-dipolar [3 + 2] azide-alkyne (CuAAC) cycloaddition), and 
has nearly become ubiquitous within the field of synthetic [bio]chemistry due to its 
speed, versatility, simplicity, regioselectivity, its broad range of applications, and its low 
toxicity within biological systems (Wang, et al., 2003; Wu, et al., 2004). One such 
modification is the PNA-like triazole-linked nucleic acid developed by Efthymiou and 
Desaulniers (2011) (Figure 6).  
 




The rationale for designing a triazole linked backbone modification was to help overcome 
the limitations caused by the polyanionic structure of the native phosphodiester linkage; 
click chemistry can introduce a neutrally-charged and physiologically stable heterocycle 
at this site. Another desirable property associated with the 1, 2, 3-triazole is its ability to 
form hydrogen bonds through N2 and N3 of the heterocycle, which could allow triazole-
linked RNAs to interact with biological molecules such as blood-serum proteins (Zhang, 
et al., 2013). 
Efthymiou and collogues demonstrated that triazole based phosphoramidites were 
compatible with solid support nucleotide synthesis and successfully incorporated into 
RNA oligonucleotides. The modified oligonucleotides were then able to form stable 
duplexes with A-form helical conformation with slightly destabilizing effects (Efthymiou 
& Desaulniers, 2011). The triazole backbone functionality was then incorporated into 
siRNA duplexes and tested for their ability to perform gene knockdown in a eukaryotic 
system. Their nuclease resistance was also assessed via incubation with serum nucleases 
for various time frames. SiRNAs containing the triazole backbone functionality were able 
to retain potent and dose dependent gene knock-down comparable to wild-type siRNAs. 
They also showed greatly enhanced nuclease stability compared to native siRNAs when 
the triazole was placed in an overhang position (Efthymiou, et al., 2012). Efthymiou and 
Desaulniers were able to demonstrate that the triazole backbone functionality was a 
viable candidate for siRNA design to help overcome therapeutic limitations. 
To further expand the utility of the triazole backbone modification it will be combined 
with 2’-ribose sugar modifications. Combining different classes of chemical 
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modifications is an area of research that is broadly ignored. Combining the 
phosphothioate backbone modification with 2’-ribose modifications is one of the only 
investigated combinations of modifications. Kraynack & Baker (2006), investigated 
siRNAs containing 2’-O-Me modifications in conjunction with phosphothioate backbone. 
They found that by incorporating a modified 2’-O-Me sense strand in combination with 
PS modifications, the siRNA duplex had increased resistance to degradation by 
nucleases, as well as prolonged serum retention while still retaining potent gene silencing 
activity. They postulated that by using 2’-O-Me modifications in conjunction with PS 
there may be increased target specificity by eliminating sense-strand-induced off-target 
gene silencing. This is thought to be due to the modulation of the thermodynamics of the 
duplex to help follow the thermodynamic asymmetry principal (Kawamata & Tomari, 
2010). One of the two only commercially available oligonucleotide therapeutics 
(Mipomersen) also combines sugar modifications with backbone modifications, 
demonstrating that combinations of chemical modifications may be the key for 
overcoming therapeutic limitations. Thus, by combining 2’-ribose modifications with 
triazole backbone modifications for the design of siRNAs, this project hopes to inform 
future chemical modification patterns which would improve the therapeutic properties of 
potential siRNA therapeutics. 
1.7 Cancer: Perfect Candidate for siRNA therapy 
SiRNA’s are poised to spark the next great revolution in cancer therapeutics. The medical 
industry is trying to move towards personalized medicine for the treatment of cancers 
(Hudson, 2013; Patel, et al., 2013) and siRNA therapy is tailored to meet the needs of 
personalized cancer medicine (Wu, et al., 2014). Cancer is the prime target for RNAi to 
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make its breakthrough as a therapeutic, as cancer is defined as unregulated cell growth 
and division caused by the mutation and misregulation of specific genes (Hanahan & 
Weinberg, 2000). Because siRNAs can be designed to knockdown any gene of interest 
based on the target mRNA sequence, the potential personalization of cancer therapeutics 
seems within grasp. 
In a landmark publication in 2000, Hanahan and Weinberg described the molecular 
hallmarks of cancer, which was further refined in 2011 (Hanahan & Weinberg, 2000 and 
2011). They summarize the molecular events which cause normal cells to become 
tumorigenic, categorized into six distinct categories: resistance of apoptosis, abundant 
cellular division signals, evasion of growth suppressor signals, tissue invasion/metastasis, 
replicative immortality and induction of angiogenesis. Through high-throughput DNA 
sequencing analyses of cancer cell genomes, each of these six phenotypic characteristics 
are explained by mutations within somatic cells. Thus, cancer is a disease characterized 
by aberrant gene expression.  
These mutations can be characterized into two distinct categories, oncogenes and tumor 
suppressor genes. Oncogenes can be considered gain of function mutations whereas 
tumor suppressor genes are loss of function mutations (Lee & Muller, 2010).  
Tumor suppressor genes (also known as anti-oncogenes) are genes which code for 
proteins which  have a dampening or repressive effect on the regulation of the cell 
cycle or promote apoptosis and sometimes both (Weinberg, 1991). Tumor suppressor 
gene mutations are considered recessive mutations because both alleles code for the 
protein, and thus both genes must be mutated to cause a phenotypic effect. When tumor 
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suppressor genes are activated they lead to one of the molecular hallmarks of cancer. Due 
to their nature they are considered loss of function mutations. 
On the other hand, oncogenes, are considered gain of function dominant mutations. 
Oncogenes evolve from proto-oncogenes. Proto-oncogenes are genes which code for 
regulatory proteins which help regulate the cellular life cycle, usually implicated in 
cellular differentiation or help regulate cell growth. These mutations are considered 
dominant mutations because it only requires one allele to become mutated for the 
phenotypic effect to be observed. Once these proto-oncogenes become mutated they 
overexpress their protein products which leads the cell to display one of the molecular 
hallmarks of cancer.  
One such oncogene is the BCL2 oncogene. The oncogenic mutation, which causes bcl-2 
to become irresponsive to apoptotic signals, is a genomic translocation event which 
moves the BCL2 gene from chromosome 18 to 14. This translocation links the BCL2 to a 
highly expressed immunoglobulin locus, leading to excessive expression (Tsujimoto, et 
al., 1984; Cory & Adams, 2002).   
Bcl-2 has a nuanced role within the cell as it is a key regulator of both apoptosis and 
autophagy; precariously maintaining the balancing between the two cellular states. 
Autophagy is a lysosomal degradation pathway which is responsible for digestion and 
recycling of bulk cellular components, such as organelles, ribosomes and protein 
aggregates. Autophagy is induced by nutrient and energy deprivation and metabolic 
stress. When autophagy is highly activated—due to excess cellular stress—it can lead to 
cell death. This cellular process is known as type-II programmed cell death. Bcl-2 plays a 
direct role in autophagic regulation by binding and inhibiting Beclin-1, a protein which 
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promotes autophagy (Pattingre, et al., 2005). A proof of concept study, demonstrating 
bcl-2s role in autophagic cell death, was published by Akar, et al. (2008). The authors 
knocked-down bcl-2 using siRNA and monitored autophagy levels, and as bcl-2 was 
knocked down, autophagic cell death increased.   
Bcl-2 plays an important regulatory role in apoptosis through its interactions with bcl-2 
family proteins (Bcl-xl, Bcl-w Mcl-1, and A1). Bcl-2 family proteins are inhibitors of 
apoptosis by supressing pro-apoptotic proteins (Bax and Bak) (Gross, et al., 1999). These 
pro-apoptotic proteins are embedded within the membrane of the mitochondria and when 
bcl-2 family proteins are absent, the pro-apoptotic proteins trigger apoptosis by disrupting 
the integrity of the outer mitochondrial membrane. This leads to the release of pro-
apoptotic signaling proteins, specifically cytochrome c. The released cytochrome c 
activates, a cascade of proteins, triggering apoptosis (Kluck, et al., 1997). The extent to 
which autophagy and apoptosis are intertwined is a heavily researched topic which 
remains unresolved.  
Because of bcl-2’s important regulatory role in both apoptosis and autophagy, BCL2 
expression within the cell is highly regulated and, when mutated, causes a disastrous 
effect within the cell.  BCL2 oncogene is a common form of mutation found in a variety 
of cancers including, melanoma, breast, prostate, chronic lymphocytic leukemia, and lung 
cancer (Tron, et al., 1995; Krajewski, et al., 1995 & 1996).  This translocation event is 
associated with chemotherapeutic resistance and poor prognosis for the patient (Debatin, 
et al., 2002). Due to BCL2 oncogene expression in a range of different cancers, and its 
therapeutic resistance, it is a good candidate for siRNA therapy.  
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This project generated a library of chemically modified siRNAs targeting the BCL2 
oncogene KB cells. By combining 2’-ribose modifications with triazole backbone 
modifications for the design of siRNAs this project hopes to inform future chemical 
modification patterns which would improve the therapeutic properties of potential siRNA 
therapeutics, by improving gene silencing, increasing nuclease resistance, and decreasing 




Chapter 2: Chemical and Physical Experimental Procedures 
2.1 Synthesis of Uracil-Triazole-Linked-Uracil Phosphoramidite Dimer 
The synthesis of the Uracil Triazole Uracil (UtU) phosphoramidite dimer was 
accomplished following the protocol of Efthymiou & Desaulniers, 2011 (illustrated in 
Scheme 1). All synthesized compounds were characterized via 
1





Scheme 1 – Synthesis of the Uracil-Triazole-Uracil Phosphoramidite 
(i) 2.5 equiv LiBH4, THF/MeOH (12:1), reflux 2  h, 63% yield of 2. (ii) 3 equiv DMT-Cl, pyridine, 24 h, 70% yield of 
3.  (iii) 3 eq TBAF, THF, 12 h, 61% yield of 4. (iv) 2 equiv 2-cyanoethyl N,N-diisopropylchlorophosphoramidite, 5.5 







hydroxyethyl)acetamido)ethyl)-1H-1,2,3-triazol-4-yl)methyl)acetamide (2). Dry THF 
was added to Compound 1 (500mg, 772 μmol) until fully dissolved under an inert N2(g) 
atmosphere. LiBH4 (1.02 mmol) was added dropwise and then reaction was refluxed until 
TLC indicated product formation and consumption of starting material, 2 h. Once the 
reaction was complete it was quenched with excess MeOH and dried down in vacuo. The 
crude product obtained was then purified using flash chromatography; the product was 
redissolved in CH2Cl2 and eluted through a silica colum using an initial mobile phase of 
10% of NH4OH in a solution of 5% MeOH in CH2Cl2, gradually increasing the MeOH 
concentration gradient to a final mobile phase of 10% NH4OH in a solution of 15% 
MeOH in CH2Cl2. The purified product, compound 2, was a white crystaline solid (295 
mg, 63%). Compound 2 was a mixture of rotamers with varying signal intesnities; 
1
H 
NMR (500 MHz, DMSO-d6) Compound 2 was a mixture of rotamers with varying signal 
intesnities; 
1
H NMR (400 MHz, DMSO-d6) δ 0.05 (s, 2H), 0.06 (s, 4H), 0.86, 0.97 (2s, 
9H), 3.26–3.34 (m, 2H), 3.43–3.74 (m, 7H), 3.82–3.89 (m, 2H), 4.38–4.40 (m, 1H), 4.48 
(t, 1.3H, J=5.62 Hz), 4.53 (t, 0.7H, J=6.25 Hz), 4.55–4.83 (m, 6H), 4.99–5.10 (m, 1H), 




triazol-1-yl)ethyl)acetamide (3). Compound 2 (175 mg,  0.271 mmol) was dissolved in 
10 mL of dry pyridine under an inert N2(g) atmosphere, was added an excess of 4,4-
dimethoxytrityl chloride (DMT-Cl) (275 mg, 0.813 mmol) until TLC analysis revealed 
the product formation and complete consumption of starting material (24 h). After the 
reaction was complete it was extracted with CH2Cl2 and washed with H2O (2X). The 
CH2Cl2 fractions were collected, pooled, and dried over Na2SO4. The extracted crude 
product was concentrated in vacuo. Once concentrated the crude product was dissolved in 
minimal amounts of CH2Cl2/MeOH and purified by flash column chromatography. The 
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silica column was performed via an eluting gradient of MeOH (5 to 15%) in CH2Cl2 to 
afford the title compound as a white solid (184 mg, 70%). Compound 3 is a mixture of 
rotamers with varying signal intensities; 
1
H NMR (400 MHz, CDCl3) δ 0.05 (s, 2H), 0.08 
(s, 4H), 0.88, 0.90 (2s, 9H), 2.90– 2.94 (m, 1.5H), 3.08–3.10 (m, 0.5H), 3.21 (t, 1.5H, J= 
4.69 Hz), 3.27 (t, 0.5H, J= 5.08 Hz), 3.32–3.31 (m, 0.2H), 3.37– 3.44 (m, 0.3H), 3.46–
3.57 (m, 2.5H), 3.60–3.64 (m, 2H), 3.74– 3.77 (m, 0.75H), 3.79, 3.80 (2s, 7H), 3.82 (t, 
1.25H, J= 4.7 Hz), 4.50 (t, 1.5H, J=5.86 Hz), 4.54 (t, 0.5H, J=5.47 Hz), 4.59 (s, 1H), 
4.62–4.64 (m, 1H), 4.67 (s, 3H), 4.72 (d, 1H, J=7.70 Hz), 5.54–5.57 (m, 1H), 5.64 (d, 
0.1H, J=1.95 Hz), 5.65 (d, 0.1H, J=1.95 Hz), 5.66–5.70 (m, 0.8H), 6.57 (d, 0.1H, J=7.82 
Hz), 6.67 (d, 0.7H, J=7.82 Hz), 6.80–6.84 (m, 4.3H), 7.07–7.09 (m, 0.8H), 7.15–7.21 (m, 
7.2H), 7.66, 7.67, 7.74, 7.85 (4s, 1H), 10.32 (s, 2H).  
N-(2-(Bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)-2-(uracil-1-yl)-N-((1-(2-(2-
(uracil-1-yl)-N-(2-hydroxyethyl)acetamido)ethyl)-1H-1,2,3-triazol-4-
yl)methyl)acetamide (4). Compound 3 (525 mg, 0.578 mmol) was dissolved in 26 mL of 
dry THF. TBAF (452 mg, 1.74 mmol) was added and the reaction was stirred for 12 h at 
room temperature and then extracted with CH2Cl2. The organic layer was washed with 
H2O and brine (2X). After organic extraction the combined organic fractions were dried 
over Na2SO4, and evaporated under reduced pressure. The crude was dissolved in 
minimal CH2Cl2/MeOH and purified by flash column chromatography, first eluting with 
100% CH2Cl2 followed by a gradient of MeOH (5 to 15%) in CH2Cl2 obtaining 
compound 4 (295 mg, 61%). Compound 4 is a mixture of rotamers with varying signal 
intensities; 
1
H NMR (400 MHz, CDCl3) δ 2.51 (s, 1H), 2.98 (s, 1H), 3.26–3.31 (m, 2H), 
3.36–3.40 (m, 3H), 3.54–3.68 (m, 4H), 3.75–3.92 (m, 8H), 4.35–4.88 (m, 8H), 5.51–5.63 
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(m, 2H), 6.63 (d, 0.2H, J= 8.56 Hz), 6.66 (d, 0.3H, J= 8.62 Hz), 6.75–6.84 (m, 4H), 7.27–
7.41 (m, 8.5H), 7.71, 7.78, 7.85, 8.03 (4s, 1H), 10.33–10.62 (m, 2H). 
2-(N-(2-(4-((N-(2-(Bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)-2-(uracil-1-
yl)acetamido)methyl)-1H-1,2,3-triazol-1-yl)ethyl)-2-(uracil-1-yl)acetamido)ethyl(2-
cyanoethyl) diisopropylphosphoramidite (5). Compound 4 (125 mg, 0.150 mmol) was 
dissolved in 5 mL of anhydrous CH2Cl2 under an inert N2 (g) atmosphere. 
Diisopropylethylamine (105 mg, 0.823 mmol), 4-dimethylaminopyridine (9.1 mg, 75.0 
μmol), and 2-cyanoethyl N,N-diisopropylchlorophosphoramidite (75 mg, 0.300 mmol) 
were then added to the solution. The reaction was mixed at RT for 4 h and when TLC 
analysis revealed consumption of starting material and formation of product the reaction 
was dried in vacuo yielding a crude product. The crude was dissolved in minimal 2% 
triethylamine in hexanes/acetone and purified by flash column chromatography eluting 
with a gradient of 2% triethylamine in acetone/hexanes (1:1 to 4:1). Once pure compound 
5 was obtained, it was a transparent solid (105 mg, 68%). Compound 5 is a mixture of 
rotamers with varying signal intensities; 
1
H NMR (400 MHz, CDCl3) δ 1.04–1.19 (m, 
12H), 2.62–2.66 (m, 3.25H), 2.94 (t, 1H, J= 4.02 Hz), 3.09 (t, 0.78H, J= 4.33 Hz), 3.22 (t, 
1.20H, J= 4.71 Hz), 3.27 (t, 0.5H, J= 4.33 Hz), 3.29– 3.37 (m, 0.25H), 3.54–3.61 (m, 
5.5H), 3.70–3.77 (m, 2H), 3.78 (s, 6.25H), 3.81–3.90 (m, 2.25H), 4.51–4.65 (m, 2.5H), 
4.72 (s, 2.5H), 4.74–4.77 (m, 1H), 5.52–5.55 (m, 1H), 5.66–5.70 (m, 1H), 6.57 (d, 0.33H, 
J=8.2 Hz), 6.65 (d, 0.66H, J ¼ 8.2 Hz), 6.82–6.86 (m, 4H), 7.27–7.31 (m, 12H), 7.71, 
7.76, 7.90, 7.96 (4s, 1H). 
35 
 
2.2 Synthesis of Anti-BCL2 Oligonucleotides through Solid Support 
Phosphoramidite Chemistry 
All β-cyanoethyl 2’-O-TBS protected, 2’-F and 2’-O-Me phosphoramidites, reagents and 
solid supports were purchased from ChemGenes Corporation and Glen Research. All 
commercial phosphoramidites were dissolved in anhydrous acetonitrile to a concentration 
of 0.1 M. The chemically synthesized UtU phosphoramidite was dissolved in 20% 
tetrahydrofuran in acetonitrile to a concentration of 0.1 M. All sequences were 
synthesized via solid support phosphoramidite chemistry using the Applied Biosystems 
394 DNA/RNA synthesizer. Oligonucleotides were synthesized on 0.2 μM dT solid 
support except for sequences that were 3’-modified, which were synthesized on 0.2 μM 
Universal-III solid supports. 1.0 μM synthesis cycles were used and all reactions were 
performed under an inert N2 atmosphere maintained at 55 psi. Commercially available 
phosphoramidites were synthesized using coupling times of 16 minutes, while chemically 
synthesized UtU coupling time was increased to 30 minutes to ensure proper coupling. 
Antisense sequences were chemically phosphorylated at the 5’-end by using 2-[2-(4,4’-
dimethoxytrityloxy)ethylsulfonyl]ethyl-(2-cyanoethyl)-(N,N-diisopropyl)-
phosphoramidite. Upon completion, columns were removed from the synthesizer, dried 
under a stream of N2, sealed and stored at 4°C until purification.  
2.3 Purification of Anti-BCL2 Oligonucleotides 
2.3.1 Removal from Solid Support and Deprotection 
Oligonucleotides were removed from their solid supports upon exposure to 1.5 ml of 
EMAM (methylamine 40% wt. in H2O and methylamine 33% wt. in ethanol, 1:1 
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(Sigma)). Columns were incubated with EMAM for 1 hour at room temperature with the 
solution in full contact with the controlled pore glass. The oligonucleotides were then 
transferred into screw cap microcentrifuge tubes and incubated overnight at room 
temperature in EMAM to deprotect the nitrogenous bases. The following day, samples 
were evaporated on a Speedvac evaporator overnight and resuspended in a solution of 
dimethylsulfoxide (DMSO): 3HF/triethylamine (TEA) (100 μl: 125 μl) (Sigma). The 
samples were then incubated at 65°C for 2.5 hours to remove the 2’-O-TBS protecting 
groups. 
2.3.2 Ethanol Precipitation 
The crude oligonucleotides were resuspended in 600 mL of pre-chilled EtOH (chilled via 
dry ice). 25 μL of 3 M NaOAc (pH 5.2) was then added and solution was mixed via 
pipetting. This solution was vortexed thoroughly and placed in dry ice for 1 hour. The 
sample was then centrifuged for 30 minutes at 12000 rpm at 4°C and supernatant was 
removed. The pelleted oligonucleotide was then resuspended in chilled EtOH. The 
process was repeated four more times without adding any additional NaOAc. The sample 
was then dried down using a Speedvac evaporator for 16 hours. 
2.3.3 Oligonucleotide Quantification 
The concentrated crude oligonucleotide sample was redissolved in 200 μL of DEPC-
treated nuclease-free water (Sigma-Aldrich). 1 μL of the RNA sample was added to 999 
μL of water in a 1-mL quartz cuvette. The diluted sample was mixed thoroughly via 
pipetting and the absorbance was measured using a spectrophotometer (Thermo 
Scientific) at 260 nm. The optical density was calculated by multiplying the absorbance 
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value calculated by the spectrophotometer by the total volume of the stock 
oligonucleotide sample (200 μL). 
2.3.4 Polyacrylamide Gel Electrophoresis of Oligonucleotides 
The polyacrylamide gel was made by mixing 30 mL of 40% acrylamide solution with 6 
mL of 10X TBE buffer (pH 8.3), 25.23 g of urea (7M final), and finally topped up to 60 
mL with of DEPC-treated nuclease-free water. The solution was vigorously stirred until 
all of the contents completely dissolved. Once dissolved, polymerization was initiated by 
adding 80 μL of 25% ammonium persulfate (APS) and 80 μL of 
tetramethylethylenediamine (TEMED). This final mixture was stirred gently for 30 
seconds and immediately loaded into the prepared gel plates. The gel was then left to sit 
for 45 minutes until it was fully polymerized. Oligonucleotide purity was assessed by 
loading the gel with 0.5 OD units of oligonucleotide with denaturing loading solution for 
a total volume of 20 μL. The gel was run using a 0.5X TBE running buffer (25 mL of 
10X TBE (pH 8.3) in 475 mL of DEPC-treated nuclease-free water) with the voltage set 
to 80V and was ran until the bromophenol blue band travelled 75% of the gel’s length (~ 
16 hours). Upon completion, the gel was stained in a 3X solution of GelRed (Biotium) 
for 30 minutes while being gently stirred on a shaker. The gel was then visualized via 
Fluorchem SP (Fisher Scientific) (Appendix Figure 2).  
2.3.5 Crush and Soak Purification of Oligonucleotides 
All strands that were purified by loading a maximum of 2 OD units of oligonucleotide per 
well. These strands were not stained were directly assessed under a short-wavelength UV 
lamp. The bands that showed the slowest migratory rate were physically excised and 
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placed into a centrifuge tube, which was further placed into a dry ice/EtOH bath for 5 
minutes. The gel pieces were then chopped up using a skinny scoopula and re-frozen in a 
dry ice/EtOH bath. The pieces were suspended in 500 μL of cold gel eluting buffer and 
chopped up further using a centrifuge pestle as they defrosted in the buffer. The slurry 
was refrozen in a dry ice/EtOH bath for 15 minutes and left to thaw for another 15 
minutes at room temperature. The slurry was then incubated for 48 hours at 37°C on a 
shaker at 200 rpm. Two days later, the slurry was centrifuged for 30 minutes at 12000 
rpm at room temperature and the supernatant was collected in a sterile microcentrifuge 
tube. The sample was then dried down using a Speedvac evaporator for 16 hours and 
another ethanol precipitation was performed as described in Section 2.3.2.  
2.3.6 Desalting of Gel Purified Oligonucleotides 
The dried down sample was redissolved in 500 μL of DEPC-treated nuclease-free water 
and transferred to an MWCO 3000 cellulose centrifugal filter where it was centrifuged at 
12000 rpm at 25°C until there was roughly 50 μL of oligonucleotide solution left (~10 
minutes). The flow-through was then discarded and 400-500 μL of DEPC-treated 
nuclease-free water was added to the remaining oligonucleotide solution before 
centrifuging the sample once again at 12000 rpm. This process was repeated for a total of 
3 times. The final 50 μL sample was transferred to a microcentrifuge tube and dried down 
using a Speedvac evaporator for 16 hours. The purified sample was then resuspended in 
100 μL DEPC-treated nuclease-free water of and quantified as described in Section 2.3.3.  
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2.3.7 Annealing Oligonucleotides for Circular Dichroisim and Mel-Temp 
Circular dichroisim (CD) spectroscopy and UV-monitored thermal denaturation were 
performed on a Jasco J-815 CD equipped with temperature control.  Equimolar amounts 
of each RNA (2.4 nmol) were annealed to their complement in 500 µL of a sodium 
phosphate buffer. The RNA were then incubated at 95°C for 2 minutes and then cooled 
slowly to room temperature to generate siRNA duplexes used for biological assays. 
2.3.8 Annealing Oligonucleotides for Biological Assays 
At 10 µM, equimolar amounts of complimentary RNAs were combined and dried down 
in a Speedvac overnight. The RNAs were then suspended in a binding buffer (75 mM 
KCl, 50 mM Tris-HCl, 3 mM MgCl2, pH 8.3) and incubated at 95°C for 2 minutes and 
then cooled slowly to room temperature to generate siRNA duplexes used for biological 
assays. 
2.4 Biophysical Measurements of Anti-BCL2 Oligonucleotides 
2.4.1 Circular Dichroisim Measurement of Anti-BCL2 Oligonucleotides 
CD measurement of each duplex were recorded in quadruplicate from 200-300 nm at 
20°C with a screening rate of 10 nm/min and a 0.2 nm data pitch. The average of the four 
replicates was calculated using Jasco’s Spectra Manager version 2 software and adjusted 
against the baseline measurement of the sodium phosphate buffer. 
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2.4.2 Thermodynamics of Anti-BCL2 Oligonucleotides (Tm) 
Melting temperatures (Tm) of each sample were measured by setting the UV absorbance 
to 260 nm and increasing the temperature of the sample from 10 to 95°C at a rate of 
0.5°C/min with the absorbance measured at the end of each 0.5°C increment.  The 
absorbance readings were automatically adjusted to the baseline measurement of the 
sodium phosphate buffer.  The Tm values were averaged from three independent 
experiments and were calculated by using Meltwin version 3.5 software assuming the 
two-state model. 
2.4.3 Preparation of Oligonucleotides for ESI-Q-TOF Mass Spec 
All single-stranded RNAs were gradient eluted through a Zorbax Extend C18 HPLC 
column with a MeOH/H2O (5:95) solution containing 200 mM hexafluoroisopropyl 
alcohol and 8.1 mM triethylamine, and finally with 70% methanol. The eluted RNAs 
were subjected to ESI-MS (ES
-
), producing raw spectra of multiply-charged anions and 
through resolved isotope deconvolution, the molecular weights of the resultant neutral 
oligonucleotides were confirmed.  The final neutral mass of the RNAs were confirmed 




Chapter 3: Biological Experimental Procedures 
3.1 Culturing of Cells  
3.1.1 Thawing of Frozen Cell Stocks 
Cryopreserved KB cells, stored in 1.5 ml of Eagle's Minimum Essential Medium 
(EMEM) (ATCC) supplemented with 5% DMSO, were removed from CryoPro® liquid 
nitrogen dewar (VWR) and slowly thawed to 25°C. Cells were reconstituted in 10 ml of 
EMEM and transferred into a 50 ml polystyrene tissue culture treated incubation flask 
(Falcon) containing 20 ml of EMEM. Cells were then incubated overnight in a Forma 
Series II CO2 Incubator (ThermoScientific) at 37°C under 5% CO2 atmosphere.  Once 
cells obtained a confluency of 90%, they were passaged normally and transferred into a 
250 ml polystyrene tissue culture treated incubation flask (Falcon) containing 25 ml of 
EMEM supplemented with 10% fetal bovine serum (FBS) (Perbio) and 1% penicillin-
streptomycin (Sigma).  
3.1.2 Sub-Culturing of KB Cells  
1x10
6
 KB cells were seeded in a 250 ml polystyrene tissue culture treated incubation 
flask (Falcon) containing 25 ml of EMEM supplemented with 10% (v/v) fetal bovine 
serum (FBS) (Perbio) and 100 U/ml penicillin and 100 mg/ml streptomycin (Sigma). 
Cells were incubated in a Forma Series II CO2 Incubator at 37°C under 5% CO2 
atmosphere until 90% confluency.  Once 90% confluency was reached, cells were 
washed 3 times with 10 ml of phosphate buffered saline (NaCl 137 mM, KCl 2.7 mM, 
PO4
3-
 10 mM, pH 7.4) (PBS). Cells were treated with 3 ml of 0.25% Trypsin (SAFC 
42 
 
Bioscience) to disperse the cells. The cells were then pelleted and resuspended in 5 ml of 
EMEM for counting. They were then diluted in EMEM to a final concentration of 1x10
6
 
cells/ml. This concentration was used for either further sub-culturing or biological assays. 
Cells were sub-cultured for no more than 10 passages total for biological assays.  
3.1.3 Cryopreservation of Cells 
KB cells were passaged normally until final resuspension of cells; cells were suspended 
in EMEM supplemented with 5% DMSO (Sigma) to a concentration of 1x10
7
 cells/ml. A 
1 ml aliquot of cells were transferred into 2 ml Fisherbrand cryogenic vials (Fisher) and 
cooled to 4°C, then frozen at -20°C and finally stored in CryoPro® liquid nitrogen dewar 
(VWR) until use.  
3.2 siRNA Transfection and qPCR Analysis of BCL2 
3.2.1 siRNA Transfection Procedure for qPCR Analysis  
50 µl of KB cells (total of 5x10
4
 cells) were added to each well of a 24-well plate 
(Falcon®) with 350 µl of growth medium and incubated at 37°C with 5% CO2. After 24 
hours of incubation, cells were treated in triplicate with 1, 10 and 20 nM concentrations 
of siRNAs using Lipofectamine 2000 (Invitrogen) in 1X Opti-Mem (ATCC). The desired 
volume of siRNAs was mixed with 25 µl of Opti-Mem in a microcentrifuge tube on ice, 
and incubated for 5 minutes. 1 µl of Lipofectamine was mixed with 25 µl of Opti-Mem in 
a microcentrifuge tube and incubated for 5 minutes at room temperature. The contents of 
the tubes were combined and incubated for 20 minutes at room temperature and 
transferred into respective wells of the tissue culture treated 24-well plate (Falcon).  
43 
 
3.2.2 RNA Isolation via TRIzol extraction 
TRIzol reagent (Ambion) is a selective way to precipitate RNA from DNA from Protein 
in a sequential manner. After homogenizing the sample with TRIzol Reagent, chloroform 
was added, and the homogenate was allowed to separate into a clear upper aqueous layer 
(containing RNA), an interphase, and a red lower organic layer (containing the DNA and 
proteins) which was discarded and not used for the purposes of this project.  
Achieving a cellular concentration of no more than 2.5 x 10
5
 cells/well (after a total 
incubation time of 48 hours) the medium was aspirated and 500 μL of TRIzol reagent 
was added to each well. The 24-well plate was then placed on a shaker set to high for 15 
minutes and then inspected under a microscope to ensure cellular lysis. The contents were 
then transferred to eppendorf tubes and 150 μL of chloroform was added to each tube. 
The tubes were then vortexed for several minutes to ensure proper mixing. The tubes 
were then rested on ice for 30 minutes or until the organic and aqueous layers were fully 
separated. The samples were then centrifuged at 11500 rpm for 15 minutes at 4°C. The 
upper aqueous later was carefully extracted and transferred into a new eppendorf tube. 
250 μL of 99.99% isopropyl alcohol (Sigma-Aldrich) was then added to each tube, then 
was mixed via inversion and finally let sit on ice for 2 minutes to settle. The tubes were 
then centrifuged at 11500 rpm for 10 minutes at 4°C. The supernatant was then discarded 
leaving the RNA pellet intact. The pellet was then washed with 550 μL of 75% EtOH 
(diluted with nuclease free water) and then briefly vortexed until the pellet was 
resuspended. The samples were then centrifuged at 9200 rpm for 5 minutes at 4
o
C. The 
EtOH was then removed, leaving the pellet. The samples were then redissolved in 40 μL 
of nuclease free DEPC treated water and placed in a 55°C water bath for 12 minutes to 
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aid in dissolving of the pellets. Once fully dissolved the samples were pulse centrifuged, 
placed on ice and then quantified and qualified outlined in sections 3.2.3 and 3.2.4.  
3.2.3 RNA Quantification 
RNA was quantified (quantity and quality) by measuring absorbance at 230 nm, 260 nm 
and 280 nm using GENESYS™ 10S UV-Vis Spectrophotometer (Thermo). 
Concentration of RNA was determined using beer-lamberts law:  
𝐴 =  𝜀 𝑐 𝑙 
Where A= absorbance at 260 nm, ε = extinction coefficient (which is 0.025 (μg/ml) cm
-1
 
for single stranded RNA), c= concentration of sample, and l= path length, which can be 





And finally RNA concentration was calculated using:  
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑠𝑠𝑅𝑁𝐴 =
𝑂𝐷260 𝑛𝑚
𝑃𝑎𝑡ℎ𝑒𝑛𝑔𝑡ℎ
 ×  𝜀 × 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝐹𝑎𝑐𝑡𝑜𝑟 
Protein contamination was calculated using absorbance at 280 nm. To estimate nucleic 
acid purity the absorbance OD 260 nm was divided by absorbance OD 280 nm. If the 
ratio of OD 260 nm/OD 280 nm was between 1.9 and 2.0 the RNA was used for cDNA 
synthesis, if lower the RNA was not used for cDNA synthesis. Contamination by 
phenolate ions, thiocyanates, and other organic compounds from RNA extraction from 
section 3.2.1 was assessed at OD 230 nm. Samples with a low 260/230—below 1.8—
have a significant presence of organic contaminants that interfere with other downstream 
processes as PCR inhibitors, therefore only RNA with an OD 260 nm/ OD 230 nm of 2 or 
higher was used for cDNA synthesis.  
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3.2.4 Assessment of RNA Integrity  
RNA integrity was visualized using a 1% agarose gel in 1X TAE buffer. 1X TAE buffer 
(40 mM Tris-OH, 20 mM Acetic Acid, pH 7.8) was prepared using 20 mL of 50X TAE 
buffer in 980 mL of water. 1% Agarose gel was prepared by dissolving 0.3 g of agarose 
in 30 mL of 1X TEA buffer which was then placed in the microwave on high for 1 
minute to completely dissolve the agarose (stopping to stir every 15 seconds). The 
agarose gel was then placed in the gel cast to solidify for 45 minutes. Once solid the gel 
was solidified it was placed in the electrophoresis apparatus and filled with 1X TAE 
buffer. 10 μL of RNA samples (5 μg of RNA total) were then loaded into each well and 
the gel was ran at 60V for 45 minutes. Once the bands had migrated 80% of the distance 
of the gel electrophoresis was stopped. The gel was stained in a 3X solution of GelRed 
(Biotium) for 30 minutes while being gently stirred on a shaker. Finally RNA integrity 
was visualized via Fluorchem SP (Fisher Scientific) (Appendix Figure 3). 
3.2.5 cDNA Synthesis 
1 µg of RNA was used for cDNA synthesis using the iScript reverse transcription kit 
(Biorad). Final volumes of 20 μL per reaction were used for the reverse transcription 
reactions: 4 μL  of iScript advanced reaction mix, 1 μL  of iScript advanced reverse 
transcriptase, 10 μL  of water, and 5 μL  of RNA sample were combined in a 
microeppendorf tube on ice. The samples were mixed via pipetting and pulse centrifuged 
to concentrate. Reverse transcription was performed at 25°C for 5 minutes, 42°C for 30 
minutes, and 85°C for 5 minutes using a PX2 thermocycler (Thermo). cDNA samples 
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were either used immediately or stored at -20°C for real time quantitative polymerase 
chain reaction (qPCR).  
3.2.6 qPCR Analysis of BCL2 
Relative transcript levels were quantified via qPCR using CFX Connect™ Real-Time 
PCR Detection System (Biorad). Standard curves were generated for each gene (BCL2, 
18s rRNA and GAPDH) to evaluate primer efficiency. The qPCR was performed in 
triplicate using the following conditions: 2 µl of cDNA, and 10 µl of SsoFast EvaGreen 
Supermix (Biorad) with respective primer concentrations and topped up to a final volume 
of 20 µl using water (DEPC water was not used during qPCR as it could potentially 
inhibit the polymerase enzyme). 1 µl of Bcl-2 forward primer: 5’- 
CTGGTGGGAGCTTGCATCAC -3’ and reverse primer:  5’- 
ACAGCCTGCAGCTTTGTTTC -3’ were used for a final concentration of 500 nM. 1.6 
µl of GAPDH forward primer: 5’-ACTTTGTGAAGCTCATTTCCTGGTA -3’ and 
reverse primer: 5’- GTGGTTTGAGGGCTCTTACTCCTT -3’ were used for a final 
concentration of 800 nM. 2 µl of 18s forward primer: 5’- 
CGGCTACCACATCCAAGGAAG- 3’ and reverse primer: 5’- 
CGCTCCCAAGATCCAACTACTAC- 3’ for a final concentration of 100 nM. 
Thermocycler conditions included an initial denaturation and enzyme activation at 95°C 
for 2 min, followed by 40 cycles of 95°C for 2 seconds, 52°C for 15 seconds, and 72°C 
for 5 seconds. Fluorescence was measured during the end of each extension phase. After 
40 cycles, a melting curve was generated by slowly increasing the temperature from 65°C 
to 95°C at a rate of 0.1°C/s, while fluorescence was measured at each increment. To 
ensure no genomic contamination, a control lacking reverse transcriptase was used for 
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each cDNA sample. No template controls were run for every set of primers. Normalized 
relative gene expression (ΔΔCq) of Bcl-2 was calculated against both reference genes 
(GAPDH and 18s) and corrected for primer efficiency using CFX Manager Software 
(BIORAD). 
3.3 Nuclease Stability Assay 
At a concentration of 12 µM, 2 µl of siRNAs Bwt, B2, B3, B10, B11, and B12 were 
incubated with 8 µl of 13.5% fetal bovine serum at 37
o
C for 0.5, 1, 2, 3, 4, and 5 hours. 
After incubation, siRNAs were resolved via electrophoresis through the use of a non-
denaturing 20% polyacrylamide gel. The polyacrylamide gel was made as described in 
section 2.3.4, but with the absence of urea. This final mixture was stirred gently for 30 
seconds and immediately loaded into the prepared gel plates. Once loaded the gel was ran 
at 60V for 24 hours. After 24 hours the gel was stained using 3X GelRed
 
(Biotium) 
nucleic acid dye for 30 minutes and then visualized via Fluorchem SP (Fisher Scientific).  
3.4 XTT Cellular Proliferation Assay 
The XTT cell proliferation assay was first described by Scudiero, et al., 1988 and was 
used to measure cell growth and drug sensitivity in tumor cell lines. The tetrazolium dye, 
2,3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT), can 
be used in cell proliferation, cytotoxicity, and apoptosis assays for adherent and non-
adherent cell cultures. XTT salt is reduced by living eukaryotic cells into a brightly 
colored orange derivative. The XTT derivative created from living cells can be measured 
at absorbance 475 nm which can be used in a relative manner to determine the cellular 
proliferation rates. This project uses the XTT assay to determine the cellular proliferation 
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rates of cells treated with anti-BCL2 siRNAs, untreated control groups and a non-target 
siRNA negative control groups.  
3.4.1 Optimization of Proliferation Assay 
Before the XTT assay could be conducted the number of cells and incubations times 
needed to be optimized to determine the highest fidelity results possible. In order to 
determine the optimal number of cells to seed 2.5x serial dilution of cells were plated in 
triplicate in tissue culture treated 96-well plate (Falcon) from 1.0 x 10 
5
  cells/well to 65 
cells/well. 200 μL of each cell dilution in triplicate or 200 μL of media only was plated 
into each well and incubated at 37°C with 5% CO2 for 48 hours. After 48 hours of 
incubation, each well was treated with 50 µl of XTT, activated by 2% N-methyl 
dibenzopyrazine methyl sulfate and incubated for 2 hours at 37°C with 5% CO2. After 2 
hours of incubation, absorbance was measured at 475 nm and 660 nm using an xMark™ 
Microplate Absorbance Spectrophotometer (Biorad). Specific absorbance was calculated 
via: A475 nm (experimental)–A475 nm (Blank)–A660 nm (experimental) and a standard 
curve was created to determine the optimal amount of cells to plate for the XTT assay. 
3.4.2 siRNA Transfection and Procedure for XTT Assay 
Once the optimal number of cells was determined 50 μL of KB cells (2.5 x 10
3
 KB 
cells/well) were seeded into each well of a tissue culture treated 96-well plate (Falcon) 
with 150 µl of growth media and incubated at 37°C with 5% CO2 for 24 hours. After 24 
hours of incubation, cells were transfected in triplicate with siRNA 1 through 29 at three 
concentrations (1, 10 and 20 nM) using Lipofectamine 2000 in 1X Opti-Mem according 
to the manufacturer’s protocol. Cells were then incubated for 24 hours at 37°C with 5% 
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CO2. After 24 hours of incubation, cells were treated with 50 µl of XTT, activated by 2% 
N-methyl dibenzopyrazine methyl sulfate and incubated for 2 hours at 37°C with 5% 
CO2. After 2 hours of incubation, absorbance was measured at 475 nm and 660 nm using 
an xMark™ Microplate Absorbance Spectrophotometer (Biorad). Specific absorbance 
was calculated via: A475 nm (experimental)–A475 nm (Blank)–A660 nm (experimental) and 
results were normalized to an untreated control. 
3.4.3 XTT Time Course Procedure 
Cellular proliferation was determined using XTT Cell Proliferation Assay Kit (ATCC®) 
for siRNAs: Bwt, B2, B3, B4, B5, B6, B10, B11, B12, and NC. Cells were seeded at 
concentrations required to reach 90% confluency at each end point (1, 2, 3 and 4 days 
post-transfection). After 24 hours of incubation, cells were transfected in triplicate with 
20 nM of respective siRNAs using Lipofectamine 2000 in 1X Opti-Mem according to the 
manufacturer’s protocol. Cells were incubated at 37°C with 5% CO2. Cells were 
transfected again following the same procedure every 48 hours. At each end point, 50 µl 
of XTT was added to siRNA-treated cells, activated by 2% N-methyl dibenzopyrazine 
methyl sulfate and incubated for 2 hours at 37°C with 5% CO2. After 2 hours of 
incubation, absorbance was measured at 475 nm and 660 nm using an xMark™ 
Microplate Absorbance Spectrophotometer (Biorad). Specific absorbance was calculated 
via A475 nm (experimental)–A475 nm (Blank)–A660 nm (experimental) and results were 
normalized to an untreated control.  
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3.5 Human Interferon Alpha ELISA Assay  
3.5.1 Isolation of Human Peripheral Blood Mononuclear Cells 
After ethical approval from the University Of Ontario Institute Of Technology’s Research 
Ethics Board, human blood was obtained from consenting normal healthy donors 
(University of Ontario Institute of Technology, Oshawa, Ontario) (Appendix Figure 1).  
Human blood (9 volumes; 30 mL) was collected in 50 ml syringes prefilled with 3.2% 
(w/v) trisodium citrate as an anti-coagulation agent and were immediately diluted with 30 
mL of balanced salt solution (D-glucose 0.1%, CaCl2 0.05 mM, MgCl2 0.98 mM, KCl 5.4 
mM, and TRIS 0.145 M).  Peripheral blood mononuclear cells (PBMCs) were prepared 
by density gradient centrifugation using Ficoll separating solution (GE Healthcare). Into 
50 mL centrifuge tubes (Falcon), pre-filled with 3ml of Ficoll, 4ml of blood was carefully 
layered on-top of the Ficoll. The centrifuge tubes were then centrifuged at 400 g for 40 
minutes at room temperature. The buffy coat layer from each centrifuge tube was then 
isolated and pooled into a clean 50 mL centrifuge tube. Three volumes of balanced salt 
solution was added to the tube and it was mixed gently via inversion before 
centrifugation at 100 g for 10 minutes at room temperature. The supernatant was removed 
and the PBMC pellet was resuspended in an equal volume of balanced salt solution. The 
sample was then centrifuged at 100 g for 10 minutes at room temperature and the 
supernatant was discarded. The PBMC pellet was then suspended in 5 mL of RPMI 1640 
(ATCC) supplemented with 10% (v/v) FBS, 1 mM L-glutamine. Isolated PBMC cells 
were counted in a haemocytometer. 4.0×10
5
 cells were seeded in a 96-well plate 
containing 200 μl RPMI 1640 (ATCC) supplemented with 10% (v/v) FBS, 1 mM L-
glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin. 
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3.5.2 Transfection of PBMCs and ELISA Preparation 
4.0×10
5
 cells were seeded in a tissue culture treated 96-well plate containing 200 μl 
RPMI 1640 (ATCC) supplemented with 10% (v/v) FBS, 1 mM L-glutamine, 100 U/ml 
penicillin and 100 mg/ml streptomycin for a total volume of 150 μl per well. Once seeded 
into the 96-well plate the PBMC cells were immediately stimulated in triplicate using 20 
nM of siRNAs: Bwt, B2, B3, B4, B5, B6, B10, B11, B12, and NC, following the 
transfection procedures in section 3.4.2. 24 hours post siRNA transfection, culture plates 
were centrifuged at 400 g for 10 minutes at 4°C and the supernatant was collected. The 
supernatant was kept on ice and directly processed with Verikine ELISA kits (PBL).  
3.5.2 Human interferon-α ELISA Procedure 
Human interferon-α (IFN-α) levels were measured according to the manufacturer’s 
protocol (PBL) using purified IFN- α standard to construct standard curves and 
supernatant from the PBMCs to test the unknown levels of IFN-α. The PBMCs 
supernatant was diluted 1:1 with supplied diluent from the kit. To each well of the ELISA 
plate 100 μL of either IFN-α or supernatant was added (in technical duplicates), the plate 
was then covered and incubated at room temperature for an hour. The wells were then 
washed once with the supplied wash buffer solution. Once the wells were washed 100 μL 
of the antibody solution was added to each well, the plate was then covered and incubated 
for an hour. After one hour the plate was emptied and each well was washed three times 
with the supplied wash buffer solution. After the wash 100 μL of the HRP solution was 
added to each well, which was then covered and incubated for one hour. After one hour 
of incubation the plate was washed four times with the supplied wash buffer solution and 
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100 μL of the TMB solution was added to each well, and then incubated in the dark for 
15 minutes. After 15minutes stop solution was added to each well and absorbance was 
measured at 450 nm using xMark™ Microplate Absorbance Spectrophotometer (Biorad). 
A standard curve was constructed using the four parameter logistic (4-PL) curve fit and 
experimental concentrations of IFN- α were calculated using the generated curve 




Chapter 4: Results and Discussion 
4.1 Sequences of siRNAs Generated 
The sequences of the siRNAs generated for this project are listed in table below  (Table 
1). The modification patterns were variations upon a theme. The optimal placement of the 
UtU modification was determined by the research of Efthymiou & Desaulniers (2012). 
When placed within an siRNA the UtU modification retained the best gene silencing 
ability when placed near the 3’-end or 3’-overhang of the sense strand. However, in this 
study, an exogenous luciferase assay gene was used.  To assess a more clinically relevant 
endogenous system, this study aimed at generating siRNAs containing a combination of 
modifications that target BCL2.   
As such, in this work the 2’-F and 2’-O-Me modifications were placed at varying 
locations within the sense and anti-sense strands. The 2’-ribose modifications within the 
sense strand had one of two modification patterns, either clustered around the 3’-end of 
the sense strand, or found throughout the entirety of the sense strand. On the anti-sense 
strand the 2’-modifications were either on the pyrimidine bases near the 5’-end or 
clustered around the 3’- end of the strand. The other pattern for 2’-ribose modifications 
was their placement on pyrimidines within the antisense strand.  The placement of these 
chemical modifications were informed by the thermodynamic asymmetry principal of 
siRNA strand selection: the strand that is most likely to be taken up by the RISC complex 
is the least thermodynamically stable 5’- end (Kawamata & Tomari, 2010). Therefore the 
2’-O-Me and 2’-F modifications—which are thermodnyamically stabalizing 
modifications (Sabahi, et al., 2001; Wang & Kool, 1995) —were placed around the 3’-
end of the sense strand to stabalize the 5’-end of the anti-sense strand, so that it is more 
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likely to be taken up by RISC. Efthymiou & Desaulniers (2012) determined that the UtU 
modification was destabilizing and was therefore placed near the 3’-end or on the 3’-
overhang of the sense strand.  









Bwt 5’-GCCUUCUUUGAGUUCGGUGtt -3’  
3’-ttCGGAAGAAACUCAAGCCAC-5’ 
 





B16 5’-GCCUUCUUUGAGUUCGGUGtt -3’  
3’-ttCGGAAGAAACUCAAGCCAC-5’ 





B4 5’-GCCUUCUUUGAGUUCGGUGtt -3’  
3’-ttCGGAAGAAACUCAAGCCAC-5’ 
 





B19 5’-GCCUUCUUUGAGUUCGGUGtt -3’  
3’-ttCGGAAGAAACUCAAGCCAC-5’ 





B7 5’-GCCUUCUUUGAGUUCGGUGtt -3’  
3’-ttCGGAAGAAACUCAAGCCAC-5’ 
 





B22 5’-GCCUUCUUUGAGUUCGGUGtt -3’  
3’-ttCGGAAGAAACUCAAGCCAC-5’ 





B10 5’-GCCUUCUUUGAGUUCGGUGtt -3’  
3’-ttCGGAAGAAACUCAAGCCAC-5’ 
 





B25 5’-GCCUUCUUUGAGUUCGGUGtt -3’  
3’-ttCGGAAGAAACUCAAGCCAC-5’ 





B13 5’-GCCUUCUUUGAGUUCGGUGtt-3’  
3’-ttCGGAAGAAACUCAAGCCAC-5’ 
 




NC 5'-CUUACGCUGAGUACUUCGAtt-3'       
3'-ttGAAUGCGACUCAUGAAGCU-5' 
Wild-type and Modified Anti-BCL2 siRNAs  
UtU= Uracil Triazole Uracil. Red= 2’-O-Me. Green= 2’-F. NC= Negative Control (Anti-Luciferase siRNA).  
The top strand corresponds to the sense strand; the bottom strand corresponds to the antisense strand.  




Several of the siRNAs were used for several experiments beyond the qPCR screen, they 
are outlined in Table 2 below.  








































Wild-type and Modified Anti-BCL2 siRNAs UtU= Uracil Triazole Uracil. Red= 2’-O-Me. Green= 2’-F. NC= Negative 
Control (Anti-Luciferase siRNA). The top strand corresponds to the sense strand; the bottom strand corresponds to the 




4.2 Circular Dichroisim 
Circular dichroisim was performed for all siRNAs generated to investigate the secondary 
structure and what effect, if any, the chemical modifications had on the secondary 
structure of the siRNAs. All the siRNAs showed characteristic peaks of A-form helix; 
they all showed a positive spike in the CD band at 260 nm, a negative spike CD band at 
210 nm, and a very shallow dip between 290-300 nm (Ranjbar, 2009). The CD spectra 
are broken up into groups to better see the trends.  
The first group being: Bwt, B2-6, B10-12, and B16-18. This group of siRNAs contained 
2’-modifications on the 3’-end of the sense strand with and without the UtU modification 




Figure 7 - The RNA duplex conformation of anti-BCL2 siRNAs, containing UtU modifications on the sense strand and 
2’-ribose modifications located about the 3’-end of the sense strand, displayed through circular dichroism 
spectroscopy. 
Wild-type and modified anti-BCL2 siRNAs (~2.4 nmol/duplex) were suspended in 500 μL of a sodium phosphate buffer 
(90 mM NaCl, 10 mM Na2HPO4, 1 mM EDTA, pH 7) and the solution was scanned from 200–300 nm at 20°C. All 
scans were performed in quadruplicate and averaged using version 2 of Jasco’s Spectra Manager software. 
 
 
The second group (B7-9, and B13-15) had full 2’-modification on the sense strand in 


































Figure 8 - The RNA duplex conformation of anti-BCL2 siRNAs, containing UtU modifications on the sense strand and 
2’-ribose modifications located throughout the entire sense strand, displayed through circular dichroism spectroscopy. 
Wild-type and modified anti-BCL2 siRNAs (~2.4 nmol/duplex) were suspended in 500 μL of a sodium phosphate buffer 
(90 mM NaCl, 10 mM Na2HPO4, 1 mM EDTA, pH 7) and the solution was scanned from 200–300 nm at 20°C. All 
scans were performed in quadruplicate and averaged using version 2 of Jasco’s Spectra Manager software. 
 
 
 The final group (B19-27) were sequences which contained 2’-modification of the sense 




























Figure 9 - The RNA duplex conformation of anti-BCL2 siRNAs, containing UtU modifications on the sense strand and 
2’-ribose modifications located throughout the sense strand and anti-sense strand, displayed through circular 
dichroism spectroscopy. 
Wild-type and modified anti-BCL2 siRNAs (~2.4 nmol/duplex) were suspended in 500 μL of a sodium phosphate buffer 
(90 mM NaCl, 10 mM Na2HPO4, 1 mM EDTA, pH 7) and the solution was scanned from 200–300 nm at 20°C. All 
scans were performed in quadruplicate and averaged using version 2 of Jasco’s Spectra Manager software. 
 
 

































Figure 10 - The RNA duplex conformation of all anti-BCL2 siRNAs displayed through circular dichroism spectroscopy. 
Wild-type and modified anti-BCL2 siRNAs (~2.4 nmol/duplex) were suspended in 500 μL of a sodium phosphate buffer 
(90 mM NaCl, 10 mM Na2HPO4, 1 mM EDTA, pH 7) and the solution was scanned from 200–300 nm at 20°C. All 
scans were performed in quadruplicate and averaged using version 2 of Jasco’s Spectra Manager software. 
 
 
All of the siRNA generated are confirmed to be in the A-form as opposed to the other 
common conformations, B-form and Z-form. The most common conformation of DNA is 
B-form helixes. These B-form duplexes are characterized by a positive long wavelength 
band or bands at about 260–280 nm and a large negative band around 245 nm (Kypr, et 
al., 2009). Another, less common, conformation is Z-form. Z-form closely resembles an 
inversion of the B-form conformation; it contains a negative band at about 290 nm, a 
positive band around 260 nm and another characteristic, extremely deep negative band at 

















































generated for this project retain their A-form helical conformation and the chemical 
modifications did not greatly deviate the secondary structure of the duplexes. Because 
they retain their A-form conformation the chemically modified siRNAs generated should 
be compatible within the RNAi pathway (Ranjbar, 2009) (Chiu & Rana, 2002) (Kypr, et 
al., 2009). 
4.3 Thermodynamics of siRNA (Tm) 
The thermodynamic properties of the siRNAs were assessed by measuring the specific 
melting temperature of the siRNA duplexes. The melting temperature (Tm) of double 
stranded nucleotides is defined as the temperature at which 50% of all molecules of a 
given DNA sequence are hybridized into a double strand, and 50% are present as single 
strands. The Tm of oligonucleotides is affected by two main factors, external factors (such 
as salt concentration, length of sequence, and concentration of the sample) and internal 
factors such as base pair composition and secondary structures. The Tms and the ΔTms of 













Bwt 75.5 0.0 
B2 72.3 -3.1 
B3 75.6 0.2 
B4 76.4 1.0 
B5 76.1 0.7 
B6 76.6 1.2 
B7 78.3 2.9 
B8 76.5 1.0 
B9 78.5 3.0 
B10 78.3 2.9 
B11 76.5 1.0 
B12 78.5 3.0 
B13 76.7 1.3 
B14 75.8 0.3 
B15 76.9 1.4 
B16 79.3 3.9 
B17 79.1 3.7 
B18 79.5 4.1 
B19 77.2 1.8 
B20 76.9 1.5 
B21 78.0 2.5 
B22 83.1 7.6 
B23 81.9 6.5 
B24 83.4 8.0 
B25 81.8 6.3 
B26 80.6 5.1 
B27 81.9 6.4 
The siRNAs (~2.4 nmol/duplex) were suspended in 500 μL of a sodium phosphate buffer (90 mM NaCl, 10 mM 
Na2HPO4, 1 mM EDTA, pH 7) and Tm’s were measured in triplicate at 260 nm, from 10-95°C. The temperature was 
increased at a rate of 0.5°C/min and the absorbance was measured at the end of every 0.5°C increment. The Tm’s of 
three independent experiments were averaged and calculated using Meltwin version 3.5 software assuming the two-
state model. 
The Tm the unmodified wild-type (Bwt) siRNA was 75.5°C, which was the predicted 
value calculated using the Oligoanalyzer tool (nearest-neighbor two-state model). B2, 
which had an internal UtU modification, showed a decreased Tm of 72.3°C (ΔTm of -
3.1°C). B3, which had a UtU overhang, showed a very slight increase of Tm of 75.6°C 
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(ΔTm of 0.2°C). These results are consistent with those of Efthymiou & Desaulniers, 
2011; when UtU was placed internally the Tm decreased and when UtU was placed in an 
overhang position the Tm was either slightly increased or slightly decreased (negligibly 
affcting the thermodynamics of the duplex). The 2’-ribose modifications used in this 
project—2’-O-Me and 2’-F—are known to be stabalizing modifications which increase 
the thermodynamic stability of the duplex (Sabahi, et al., 2001; Wang & Kool, 1995). 
When 2’-O-Me was partially incorperated throughout the sense strand (B4) the Tm of the 
duplex increased to 76.4°C (ΔTm of 1.0°C). When the 2’-F modification was partially 
incorperated throughout the sense strand (B10) the Tm of the duplex increased to 76.7°C 
(ΔTm of 1.3°C). When a mixed sequence of 2’-F and 2’-O-Me bases were partially 
incorporated within the sense strand of the duplex the Tm increased to 77.2°C (ΔTm of 
1.8°C). When 2’-O-Me and 2’-F modifications were placed throughout the entirety of the 
sense strand (B7 and B13) the Tm of the duplexes increase to 78.3°C and 79.3°C, 
respectively (ΔTm of 2.9°C and 3.9°C).  When the sense and anti-sense strands had 2’-
ribose modification the Tm of the duplex increased even more; B19-27 all had 2’-ribose 
modifications on the sense and anti-sense strands and showed the highest thermodynamic 
stability. When 2’-F modifications were partially incorporated into the sense and anti-
sense strand (B19) the Tm of the duplex had a sharp increased to 83.1°C (ΔTm of 7.6°C). 
When 2’-F were incorporated into the sense strand and a mixture of 2’-O-Me and 2’-F 
were incorporated into the anti-sense strand (B22) the Tm increased to 81.8°C  (ΔTm of 
6.3°C). Finally when a mixed sequence of 2’-O-Me and 2’-F were incorporated into the 
sense and anti-sense strands (B25) the Tm increased to 83.9°C (ΔTm of 8.4°C).  When 
UtU was placed internally with any of the 2’-ribose modification patterns (B5, B8, B11, 
64 
 
B14, B17, B20, B23, and B26) it had a thermodynamically destabilizing effect, lowering 
the Tm of the all the duplexes without an internal UtU modification (with an average ΔTm 
of -1.4°C vs equivalent duplexes without internal UtU). These results confirm that 
internal UtU placement is thermodynamically destabilizing and may aid in strand 
selection when designing chemically modified siRNAs. When UtU was placed at the 
overhang position it had a negligible effect on the thermodynamics of the duplex with an 
average ΔTm of 0.2°C vs equivalent duplexes without a UtU overhang. Overall the 
thermodynamics of the siRNAs were as predicted, which should translate into better gene 
knockdown results and potentially better strand selection by RISC (Kawamata & Tomari, 
2010).  
4.4 Masses of Synthesized Oligonucleotides 
To ensure all chemical modifications were successfully incorporated into the synthetic 
oligonucleotides the masses of each oligonucleotide was determined using electrospray 
ionizing quantitative time-of-flight mass spectrometry (ESI Q-TOF). All oligonucleotides 











1 6618.84 6618.83  5’- GCCUUCUUUGAGUUCGGUGtt -3’ 
2 6586.05 6586.02 5’- GCCUUCUUUGAGUtUCGGUGtt -3’ 
3 6604.02 6604.00 5’- GCCUUCUUUGAGUUCGGUGUtU -3’ 
4 6725.96 6725.97 5’- GCCUUCUUUGAGUUCGGUGtt -3’  
5 6712.29 6712.14 5’- GCCUUCUUUGAGUtUCGGUGtt -3’ 
6 6744.29 6744.05 5’- GCCUUCUUUGAGUUCGGUGUtU -3’ 
7 6841.37 6841.08 5’- GCCUUCUUUGAGUUCGGUGtt -3’  
8 6851.23 6851.27 5’- GCCUUCUUUGAGUtUCGGUGtt -3’ 
9 6856.50 6856.17 5’- GCCUUCUUUGAGUUCGGUGUtU -3’  
10 6629.81 6629.80 5’- GCCUUCUUUGAGUUCGGUGtt -3’  
11 6616.01 6616.04 5’- GCCUUCUUUGAGUtUCGGUGtt -3’ 
12 6603.93 6603.82 5’- GCCUUCUUUGAGUUCGGUGUtU -3’  
13 6652.79 6652.77 5’- GCCUUCUUUGAGUUCGGUGtt -3’ 
14 6783.88 6784.83 5’- GCCUUCUUUGAGUtUCGGUGtt -3’  
15 6683.940 6684.11 5’- GCCUUCUUUGAGUUCGGUGUtU -3’  
16 6685.87 6685.86 5’- GCCUUCUUUGAGUUCGGUGtt -3’  
17 6678.99 6678.17 5’- GCCUUCUUUGAGUtUCGGUGtt -3’  
18 6672.07 6672.83 5’- GCCUUCUUUGAGUUCGGUGUtU -3’ 
23 6697.18 6697.01 5’-ph-CACCGAACUCAAAGAAGGCtt-3’ 
24 6792.01 6791.94 5’-ph-CACCGAACUCAAAGAAGGCtt-3’ 
25 6771.08 6771.06 5’-ph-CACCGAACUCAAAGAAGGCtt-3’ 
ESI Q-TOF were recorded in a negative electrospray mode after HPLC elution using two mobile phases; MeOH/H2O 
5:95 (v/v) with 200 mM hexafluoroisopropyl alcohol and 8.1 mM triethylamine, and 70% MeOH.UtU= Uracil Triazole 
Uracil. Green= 2’-F Modification. Red= 2’-O-Me Modification. ph= 5’-phosphate. 
 
4.5 Nuclease Stability Assay 
It has been previously reported that UtU and 2’-O-Me modifications incur nuclease 
stability when compared to unmodified siRNAs (Efthymiou, et al., 2012; Egil, et al., 
2005; Allerson, et al., 2005). To test the serum nuclease stability unmodified and 
modified siRNAs (Bwt, B2, B3, B4, B5, and B6) were incubated in fetal bovine serum 
(FBS) for up to five hours to analyze the truncated products in a time-dependent manner 
using polyacrylamide gel electrophoresis (Figure 11). For this study 2’-F modifications 
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were not assessed because literature has shown that they provide little to no nuclease 
stability protection over unmodified siRNAs (Manoharan, 1999). 
 
Figure 11 - Nuclease stability assay of select anti-BCL2 siRNAs. 
20% Non-denaturing polyacrylamide gel with degradation products of siRNAs after incubation with 13.5% fetal bovine 
serum at 37.5oC from 0 hours to 5 hours. 
 
 
Unmodified siRNA (Bwt) degraded almost immediately, with little to no siRNA present 
within 0.5 hours of incubation in the presence of nucleases.  When the UtU modification 
was incorporated internally (B2), the full siRNA duplex persisted for up to 2 hours, and 
when placed at an overhang position (B3), the duplex was persistent for up to 4 hours. 2’-
O-Me modifications clustered around the sense strand (B4) increased nuclease stability, 
allowing the siRNA duplex to last for 2 hours in the presence of nucleases. When the 2’-
O-Me modification was combined with an internal UtU modification (B5), the duplex 
lasted up to 3 hours. When the 2’-O-Me modification was combined with the UtU 
overhang (B6), the siRNA duplex was still present after 5 hours of incubation in the 
presence of nucleases. When the 2’-O-Me modification was combined with the UtU 
backbone modification, nuclease resistance was greatly increased. Any change to the 
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native chemical structure caused a significant increase in nuclease stability, especially 
when the UtU backbone and 2’-O-Me modifications were combined. 
4.6 qPCR Assessment of Anti-BCL2 siRNAs  
4.6.1 Gene silencing ability of Anti-BCL2 siRNAs 
After biophysical properties of the library of anti-BCL2 siRNAs were measured they 
were then assessed for their ability to knock-down BCL2 mRNA in vitro in KB cell lines 
(these cells were kindly donated by DLVR Therapeutics). Cell were transfected at three 
concentrations (1nM, 10nM and 20nM), with anti-BCL2 siRNAs. 24 hours post 
transfection RNA was isolated then converted to cDNA. The cDNA was then used to 
evaluate gene expression using qPCR; expression was normalized to an untreated control 
using reference genes 18s rRNA and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). An untreated control group was transfected with an empty lipofectamine 2000 
transfection reagent and a negative control group was transfected with an anti-luciferase 
siRNA and not target any endogenous gene. Results of the initial qPCR screen are 





Figure 12 - Relative gene expression of BCL2 in KB cells using the best candidate anti-BCL2 siRNAs. 
Relative expression was measured in in KB cells 24 hours post anti-BCL2 siRNA transfections at 1 nM, 10 nM and 20 
nM. Gene expression was measured using qPCR and expression was normalized to an untreated control using 
reference genes 18s rRNA and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Untreated control was 




The initial qPCR screen showed very promising and expected results. Chemical 
modification of the siRNA constructs did not compromise gene silencing ability for most 
anti-BCL2 siRNAs. Most anti-BCL2 siRNAs showed effective dose-dependent 
knockdown of BCL2. The siRNAs that did not knock-down BCL2 were siRNAs which 
were heavily modified with 2’-ribose modifications (B7, B8, B9, B13, B14, and B15). 
Literature has shown when heavily modifying siRNA with 2’-ribose modifications the 
siRNA loses its ability to silence the target mRNA (Elbashir, et al., 2001). More recent 
studies however, have shown that when blunt-ending the construct, rather than using 3’-
overhangs, siRNAs retain their activity when heavily modified with 2’-ribose 
modifications (Kraynack & Baker, 2006). This strategy could be employed for future 
siRNA design when 2’-ribose modifications are incorporated. Another group of siRNAs 

























































































































and the anti-sense strands (B19, B20, and B25). This observation has been reported 
previously and could be due to difficulty loading the modified RNA into the RISC 
complex (Kraynack & Baker, 2006).  
Several of the chemically modified siRNAs exhibited enhanced activity compared to 
unmodified wild-type siRNA (Bwt) at concentrations at 10 nM and below (Figure 13).  
 
Figure 13 - Relative gene expression of BCL2 in KB cells using the best candidate anti-BCL2 siRNAs. 
Transfections of anti-BCL2 siRNAs at concentrations of 1 nM, 10 nM and 20 nM and gene expression was assessed 24 
after transfection. Gene expression was measured using qPCR and expression was normalized to an untreated control 
using reference genes 18s rRNA and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Untreated control was 
transfected with an empty lipofectamine 2000 transfection reagent. NC was a negative control which did not target any 
endogenous gene. 
  
From the initial screen of the siRNA library, 8 siRNAs were chosen for further 
investigation because of their dose dependent knockdown of BCL2 and enhanced activity 
over Bwt (B2, B3, B4, B5, B6, B10, B11 and B12). siRNAs which contained UtU 
modifications combined with 2’-ribose modifications clustered around the 5’-end of the 
sense strand (B2, B5, and B11)  showed enhanced gene silencing ability  compared to 













































B12), whether in conjunction with 2’-ribose modifications or not, the siRNAs showed the 
greatest silencing ability over all concentrations while retaining a dose dependent 
response. These results are similar to the results of Efthymiou, et al. 2012, when UtU was 
placed in a 3’-overhang position or near the 3’-end of a sense strand gene silencing was 
similar or better than wild-type siRNA. This could be explained by the thermodynamic 
asymetry principal, which states that RISC is more likely to take up the strand which has 
the least thermodynamically stable 5’-end (Kawamata & Tomari, 2010). Therefore, by 
placing a destabiliing modification (UtU) around the 3’-end of the sense strand and 
stabalizing modifications (2’-O-Me and 2’-F) at the 5’-end of the sense strand the anti-
sense (desired) strand is taken up by RISC. This could be the reason for the enhanced 
activity we see for these 8 siRNAs. These siRNAs were able to effictivly knock-down 
BCL2 at theraputic concentrations and are thus promising candidates for anti-cancer 
treatment.  
4.7 Anti-BCL2 XTT Cellular Proliferation Results 
4.7.1 Optimization of XTT Assay 
Before cellular proliferation assays could be carried out, the procedure needed to be 
optimized for the cell line of use, KB cells. To determine the optimal number of cells 
used to seed with a 2.5X dilution series was set up starting with 100,000 cells/well down 




Figure 14 - : Optimization of XTT cellular proliferation assay. 
KB cells were plated starting with a concentration of 100000 cells/well in a 2.5X dilution series down to 0 cells/well. 
Cells were incubated for 48 hours and then processed using XTT assay kit. Absorbance vs. cells plated was plotted and 
a sigmoidal regression was performed to determine the line of best fit to calculate the point of inflection to determine 
the optimal number of cells to plate for 48 hour experiments. 
 
 
After the results were plotted a standard curve was calculated using sigmoidal regression, 








Resulting with an R
2
 value of 0.9997. The point of inflection was calculated to be 2400 
and thus the optimal number of cells to seed for the siRNA screen experiment was 2400 
cells per well. Upon microscopic inspection 2400 cells per well ended up being the 
number of cells needed to reach confluency after 48 hours 1000 cells per well were sub-
confluent and 6400 cells per well were overgrown. Thus, moving forward with further 
experimentation with the time course assay (Section 4.7.3) the number of cells used for 
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4.7.2 Cellular Proliferation Screen with Anti-BCL2 siRNAs  
BCL2 oncogene is responsible for the overproduction of the bcl2 protein, which is a key 
regulatory protein in cellular apoptosis. The bcl-2 protein prevents pro-apoptotic factors 
from triggering type I and type II cell death, and thus overexpression of BCL2 prevents 
cells from undergoing apoptosis (Tsujimoto, et al., 1985), therefore knocking out BCL2 
should cause a decrease in cellular proliferation. An XTT cellular proliferation kit 
(ATCC) was used to determine proliferation rates of KB cells treated with anti-BCL2 
siRNA in comparison to untreated cells 24 hours post siRNA transfection (Figure 15).  
 
Figure 15 – XTT Cellular Proliferation siRNA screen.  
KB cells were plated starting with a concentration of 100000 cells/well. 24 hours later cells were transfected with 1, 10 
and 20 nM of anti-BCL2 siRNAs. 48 hours post-transfection cellular proliferation was determined via XTT cellular 
proliferation assay. Results were normalized to untreated cells and expressed as a percentage of cellular proliferation. 
A siRNA—which does not target any endogenous gene—was used as a negative control. 
 
 
The anti-BCL2 siRNAs were able to decrease cellular proliferation by 10% or more at all 
concentrations when compared to untreated cells. To ensure that the decreased cellular 
proliferation was not due to toxicity from the siRNAs a negative control was used. This 































































































































negative control showed the same cellular proliferation rate as the untreated control 
indicating that the siRNAs were not inherently toxic to the cells. Therefore, the decrease 
in proliferation rates are not due to the presence of dsRNA alone and are most likely 
associated with BCL2 knockdown due to the anti-BCL2 siRNAs. 
4.7.3 Time Course Cellular Proliferation Screen with Best Candidate Anti-BCL2 siRNAs 
From the qPCR screen, the best candidate siRNAs were used to determine cellular 
proliferation rates from continual knockdown over the course of four days using the 8 
best candidate anti-BCL2 siRNAs (transfection every 48-hours with 20nM siRNA). 
Figure 16 illustrates that mRNA levels are still depleted after 48-hours.  
 
Figure 16 – Time Course Relative gene expression of BCL2 in KB cells using the best candidate anti-BCL2 siRNAs. 
Transfections of anti-BCL2 siRNAs at 20 nM and gene expression was assessed 24 and 48 hours after transfection. 
Gene expression was measured using qPCR and expression was normalized to an untreated control using reference 
genes 18s rRNA and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Untreated control was transfected with an 
empty lipofectamine 2000 transfection reagent. NC was a negative control which did not target any endogenous gene. 
 
 
All of the best candidate siRNAs were able to decrease cellular proliferation within 24 












































Figure 17 - Time course cellular proliferation results of best candidate anti-BCL2 siRNAs.  
KB cells were plated at various concentrations (to reach confluency at each end point and transfected at 24, 48, and 72 
hours with 20 nM of anti-BCL2 siRNAs. At each end point cellular proliferation was determined via XTT cellular 
proliferation assay. Results were normalized to untreated cells and expressed as a percentage of cellular proliferation. 
A siRNA—which does not target any endogenous gene—was used as a negative control. 
 
 
Cellular proliferation continued to decrease after 48, and 72 hours. By 96 hours, cellular 
proliferation rates stabilized at their lowest rate when compared to the untreated control. 
Continual knockout of BCL2 caused a 50-60% decrease in cellular proliferation after 96 
hours compared to the untreated control. These results show that by depleting oncogene 
BCL2, cellular proliferation rates decrease, validating the potential of siRNAs as a 
therapeutic.   
4.8 Human Interferon Alpha ELISA Assay Results 
In vivo, double-stranded RNAs stimulate innate immunity by triggering the type I 
interferon response (Marques & Williams, 2005). In vitro, the immune response is highly 
dependent on the specific cell line used, and many cell lines do not possess the receptors 










































(PBMC) isolated from whole human blood is a fast and reliable in vitro approach to 
predict in vivo response (Zamanian-Daryoush, et al., 2008). Therefore, after obtaining 
ethical approval, human PBMCs were isolated from whole blood donated by healthy 
volunteers after obtaining written consent. PBMCs were stimulated using 20 nM of anti-
BCL2 siRNAs complexed with lipofectamine 2000. After 24 hours, human interferon 
alpha (IFN-α) levels were measured using a VeriKine ELISA kit (PBL Assay Science) 
according to the manufacturer's protocol (Figure 18). 
 
Figure 18 - Human interferon alpha production in response to anti-BCL2 siRNAs.  
Human PBMCs were stimulated with 20 nM of anti-BCL2 siRNAs supplemented with Lipofectamine 2000. IFN-α was 
measured in the supernatant 24 hours post-transfection by ELISA. Results were calculated based upon a high-
sensitivity standard curve (Appendix Figure 4). 
 
 
PBMCs challenged with unmodified siRNA as well as UtU modified siRNAs (Bwt, B2, 
and B3) induced IFN-α production (72.8, 74.4, and 76.9 pg ml
-1
 respectively), whereas 
siRNAs containing 2’-ribose modifications (B4, B5, B6, B10, B11 and B12) showed a 
decrease in immune response similar to untreated controls (28.8, 26.1, 27.3, 31.2, 25.4, 
and 26.1 pg ml
−1
























not alter immune response in comparison to unmodified siRNA (Bwt). However, when 
the UtU modification was combined with 2’-ribose modifications the innate immune 
response was diminished as indicated by a decrease in IFN-α production from PBMCs 
(Statistical Significance P<0.001 using student t-test). It is well established that 2’-ribose 
modifications evade immune detection (Valenzuela, et al., 2015), but backbone 
modifications (including the UtU modification) are almost unknown with respect to their 
effect on immune response. One backbone modification, the phosphothioate backbone 
modification, is not considered an immunostimulatory modification but does not reduce 
immune response as the 2’-ribose modifications do (Verthelyiemail & Zeuner, 2003) 
much in the same way the UtU modification did not affect the amount of IFN-α 
production. What is promising, however, is that the UtU modification can be combined 
with 2’-ribose modifications to overcome immune activation.  
4.9 Summary of Results 
All of the anti-BCL2 siRNAs generated showed effective dose-dependent gene 
knockdown at clinically relevant concentrations, with several siRNAs showing results 
similar or better than the wild-type anti-BCL2 siRNA. The chemically modified siRNAs 
showed increased stability in the presence of serum nucleases; the greatest stability being 
siRNAs containing 2’-O-Me in conjunction with the UtU modification. By targeting a 
clinically relevant oncogene, BCL2, cellular proliferation rates were diminished when 
siRNAs depleted BCL2. This diminished proliferation rate continued as long as the 
siRNAs were knocking down BCL2. This result indicated that by knocking down an anti-
apoptosis oncogene, normal apoptosis can occur, and proliferation rates decrease. Finally, 
the anti-BCL2 siRNAs were assessed for their ability to diminish primary interferon 
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response in human PBMC isolates. 2’-Ribose modifications were able to diminish 
immune detection whereas the UtU alone did not alter the immune response in 
comparison to wild-type siRNA, but when UtU was combined with 2’-modifications the 
immune evasion was similar to that of 2’-modifications alone. Overall, UtU can be 
combined with 2’-ribose modifications to improve the therapeutic properties of siRNAs 
without compromising its ability to knockdown target genes. This work has been 
published in the Royal Society of Chemistry Journal: Medicinal Chemistry 
Communications (Hagen, et al., 2015) and is included in the appendix (Error! Reference 




Chapter 5: Conclusions and Future Directions 
5.1 Conclusions 
siRNA oligonucleotides containing commercially available 2′-ribose modifications (2′-O-
Me/2′-F) can be combined with a novel triazole-linked backbone modification in siRNA 
design and these siRNAs are amendable within the RNAi pathway. The qPCR screens 
show that these chemical modifications have effective gene-silencing activity either 
independently or in combination. Although, these results show that there is a limit to the 
amount of modification that can be incorporated before RNAi activity diminishes; when 
the sense and anti-sense strands were heavily modified, gene silencing activity was 
severely diminished.  The optimal placement of modifications seems to follow the 
thermodynamic asymmetry rule of siRNA design (Kawamata & Tomari, 2010), the least 
thermodynamically stable 5’- end of the siRNA is taken up by RISC. Therefore, the most 
effective modification patterns were when stabilizing modifications (2’-ribose) were 
placed around the 5’-end of the sense strand, and a destabilizing modification (UtU) was 
placed around the 3’- end of the sense strand. Effective gene silencing is not the only, nor 
the main factor when designing siRNAs. There are several practical challenges to siRNA 
design which can be overcome by chemical modification. Beyond gene knockdown 
assessment of nuclease stability, immune response and phenotypic effect (cellular 
proliferation assay) were also investigated.  
After assessment of gene knockdown nuclease stability was investigated, as both 
modifications have shown serum nuclease stability over unmodified siRNAs. The 
mechanism of siRNA degradation via nucleases proceeds by transesterification, so most 
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chemical modifications which replace the hydroxyl at the 2′-position provide some 
protection from degradation in a position-specific manner. Likewise, backbone 
modifications also make RNA a less labile substrate for nucleases. As expected, the 
chemically modified siRNAs show excellent biological stability with high nuclease 
resistance, whereas unmodified siRNAs are readily degraded by serum nucleases. 
Nuclease stability was additive when combining triazole-linked backbone modifications 
with 2′-ribose modifications, especially when the triazole modification was placed at the 
overhang position. This enhanced nuclease stability is a desirable property when 
designing therapeutic siRNAs, and the chemical modification patterns employed in this 
study could be used to inform future siRNA design.  
Another major limitation of the pharmaceutical application of siRNAs is the innate 
immune response. The innate immune system has a variety of receptors which recognize 
and respond to small nucleic acids, triggering cytokine and interferon release (Marques & 
Williams, 2005). Both 2′-O-Me and 2′-F modifications block immune response in vitro 
and in vivo (Fucini, et al., 2012), whereas the triazole-linked nucleic acid had not been 
tested for immune response. Our results show that triazole-linked backbone modifications 
illicit a similar immune response as unmodified siRNAs, and are detected by the innate 
immune system. When the triazole-linked backbone modification is combined with 2′- 
ribose modified siRNAs, the immune response is diminished to a similar level as induced 
by siRNAs containing only 2′-ribose modifications. Many studies have shown that 2’-O-
Me and 2’-F modifications directly decrease innate immune response and decrease IFN-α 
production (Collingwood, et al., 2008; Judge, et al., 2006; Judge & MacLaclan, 2008). 2’-
modified siRNAs have shown to be a TLR antagonist in vitro and in vivo. Robbins and 
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collouges (2007), have shown that 2’-O-Me RNA directly inhibits cytokine induction by 
directly antagonizing TLR-7 in a non-sequence dependant manor, and postulate that 2’-F 
modifications should behave the same. Therefore, simply by placing a few 2’-ribose 
modifications within a siRNA, immune response will be greatly diminished when 
compared to native siRNAs. This should help inform future siRNA modification patterns; 
by placing a few 2’-ribose modifications within a siRNA, immune activation can be 
diminished.  
Finally, the utility of these siRNAs were assessed by targeting a clinically relevant 
oncogene, BCL2, which is implicated in a diverse range of chemotherapeutic resistant 
cancers (Reed, 1995). Not only were the siRNAs successful in knocking down BCL2 
expression in vitro, but were also able to decrease cellular proliferation rates. These 
results mirror those of oblimersen sodium (Genasense), a BCL2 antisense 
oligonucleotide. In preclinical trials, Genasense depleted BCL2 mRNA which correlated 
to increased apoptosis and decreased cellular proliferation in vitro (Herbst & Frankel, 
2004; Kang & Reynolds, 2009). A more recent study of anti-BCL2 siRNAs (Lin, et al. 
2012) generated anti-BCL2 siRNAs, containing 2’-ribose modifications. The siRNAs 
were assessed by their ability to induce tumor cell apoptosis in KB cell xenograft tumor-
bearing mice. They reported significant tumor apoptosis and significant tumor size 
reduction when mice were treated with ani-BCL2 siRNAs. Although, not measuring the 
same metric, increased apoptosis and decreased cellular proliferation are indicative of the 
same result: when bcl2, an important apoptotic regulator, is depleted tumorigenic cells no 
longer proliferate out of control and undergo apoptosis. Although, for anticancer therapy, 
knockdown of the BCL2 gene is not sufficient to achieve complete antitumor activity. 
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Beyond bcl2, there is a variety of regulatory proteins and genes which regulate the 
apoptosis state of the cell, let alone all of the other regulatory proteins and genes present. 
But, by combining of BLC2 gene knockdown with traditional chemotherapy therapeutic, 
efficacy can be enhanced in multidrug-resistant cancer cells (Saad, et al., 2008; George, 
et al., 2009; Chen, et al., 2009; Meng, et al., 2010; Pandyra, et al., 2007). Overall, by 
combining 2′-ribose modifications with a novel triazole-linked backbone modification, 
we have generated siRNAs with chemical modification patterns which have enhanced 
nuclease stability and decreased immune activity without compromising the potency of 
the duplex as a trigger of RNAi. 
Overall, by combining 2’-ribose modifications with the triazole-linked backbone 
modification several therapeutic barriers can be overcome, including, potent gene 
knockdown, nuclease stability, and innate immune response. The result of this project can 
help inform future chemical modification patterns amendable with siRNA design with the 
hopes of developing a siRNA therapeutic.  
5.2 Future Prospects 
This project have several avenues left to explore, including determining the true potency 
of these siRNAs, determining the exact molecular effects these modifications have within 
the RNAi pathway, improving the therapeutic features of these siRNAs by combining 
more modifications, and finally by bridging the results of this study to inform the design 
of novel dicer substrate siRNAs.  
The first avenue of investigation to follow up this study would be to determine the IC50 
values of the best candidate siRNAs. IC50 is a common method used by researchers and is 
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defined in siRNA research as concentration where the targeted mRNA is reduced by 
50%. This method was developed early on in siRNA research as a way to directly 
compare siRNAs with anti-sense oligonucleotides, and is now used as the standard for 
measuring siRNA potency (Far & Sczakiel, 2003; Miyagishi, et al., 2003; Alagia, et al., 
2015; Peel, et al., 2015). Thus the results of generating IC50 curves would help us 
understand the potency of the siRNAs. This would be an easy experiment to conduct; a 
dose-response curve would be constructed by transfecting cell cultures with 
concentrations of siRNA at a concentration which completely knocks down mRNA to a 
concentration that no longer affects mRNA levels within the cells. This would be a good 
follow up study because all of the best candidate siRNAs have similar knockdown values 
at the concentrations tested in the project, so by determining the IC50 values the potency 
of the siRNAs can be determined as well as understanding the subtle effects of the 
chemical modifications within the siRNAs.  
A large challenge facing siRNA therapeutics, not addressed in this study, is the inability 
of siRNAs to readily cross the cellular membrane. This is due to the polyanionic nature of 
the phosphodiester backbone, causing the siRNA to be negatively charged and thus 
unable to pass across the fatty lipid bilayer. Recently, our research group has reported the 
conjugation of cholesterol to a uracil based triazole backbone and which was placed 
within the internal region of an siRNA (Peel, et al., 2015) (Figure 19). This was the first 
time that a nonionic linkage unit derivatized with a base-modified hydrophobic group has 
been placed within a siRNA. Several other examples of base-modified siRNAs have been 
explored; however, they have been utilized within the context of a sugar linked to a 




Figure 19 – Chemical structure of cytosine-triazole linked-uracil cholesterol (CtU
CH).   
 
We investigated if the conjugation to a lipophilic molecule, such as cholesterol, would aid 
in transfection without the need of a carrier (such as lipofectamine). Without a carrier the 
CtU
CH
 had knockdown comparable to that with a carrier, indicating that it did aid in 
crossing the cellular membrane. The CtU
CH
 modification was not combined with any 
other modification. The results of this thesis project indicate that by combining the CtU
CH 
modification with 2’-ribose modifications thermodynamics could be fine-tuned and 
immune stimulation can be diminished, as the triazole modification alone does not alter 
immune response. Thus, future siRNA design could incorporate triazole modifications 
(with lipophilic conjugation) in conjunction with 2’-ribose modifications to improve all 
aspects of siRNA therapy: enhanced nuclease stability, thermodynamic modulation, 
decreased immune activation, and greater cell permeability.  
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Beyond testing the therapeutic applications of these chemically modified siRNAs it 
would be of interest to further investigate the molecular behaviour of these siRNAs 
within the RNAi pathway. The performance of the siRNAs was tested in a downstream 
way; measuring mRNA levels after gene knockdown using qPCR. It would be wise to 
test performance of native siRNAs vs modified siRNAs in strand selection assays, RISC 
assembly assays, and Argonaute loading assays to determine the true nature of the 
enhanced properties of these siRNAs within the RNAi pathway. This could help shed 
some light on the underlying mechanisms as to why the chemically modified siRNAs 
have a greater effect than native siRNAs.  
A strand selection assay is two dual luciferase assays done in tandem using psiCHECK 
vectors (Promega). The first plasmid would contain the genetic information 
corresponding to the sense strand of the siRNA while the other plasmid contains 
sequence corresponding to the anti-sense strand. This is a crude method to quantify strand 
selection in vitro and this assay would confirm the strand selection bias which the 
chemical modifications impart upon the siRNAs. The results would indicate whether the 
thermodynamic asymmetry principal does indeed hold true for strand selection bias using 
the specific chemical modification pattern employed. 
The RISC assembly assay and Argonaute loading assay would determine if the chemical 
modifications have any impact upon RISC formation in vitro and help de-convolute what 
really affects siRNA potency. There are conflicting reports as to what constitutes 
canonical RNAi, some groups report that Dicer is disposable for proper strand 
selection/RISC assembly and argonaute is only important for strand selection and RISC 
assembly, and determines the potency of the siRNA (Yoda, et al., 2010; Betancur & 
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Tomari, 2012; Ye, et al., 2011); whereas other groups believe that dicer is invaluable for 
proper RISC assembly and strand selection, and thus determines potency (Sakurai, et al., 
2011; Wang, et al., 2011; Noland, et al., 2011). The latter theory is called the hand-off 
mechanism and it is believed that siRNAs which go through dicer and form a pre-RISC 
complex before argonaute and RISC form are more potent effectors of RNAi.  Liu, et al. 
(2012) developed a step by step method to investigate RISC and argonaute loading. This 
method would be used to determine how dicer is involved in RISC loading in the 
presence of chemically modified siRNAs. The assay itself consists of incubating cell 
cultures with radiolabelled siRNAs and running native gel electrophoresis mobility shift 
assays to monitor the assembly components of the RISC complex. This is done in vitro 
cell cultures expressing differentially epitope labelled and overexpressed RISC proteins. 
This assay is now used by several labs when researching the molecular nature of RNAi 
and the potency of siRNAs (Liu, et al., 2012; Snead, et al., 2012; Yoda, et al., 2010).  
Another avenue worth exploring is chemical modifications within dicer substrate 
siRNAs. Dicer substrate siRNAs are a recent but very promising development in siRNA 
design. First described by Kim, et al. (2005), dicer substrate siRNAs (DsiRNAs) are 
siRNAs which are slightly longer than tradiational synthetic siRNAs. These DsiRNAs are 
first processed by dicer and then loaded into RISC in contrast to siRNAs which bypass 
dicer. Through refinment, DsiRNAs have proven to be up to 100-times more potent and 
longer lasting gene knockdown when comparied to siRNAs without any chemical 
modifications, also showing decresed immune activation in compairason to native 
siRNAs, completely diminishing the primary immune response (Snead, et al., 2012). 
There has been much commercial interest in DsiRNAs, as several nucleic acid research 
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companies have developed DsiRNA products (Bio-Rad and IDT) as well as several 
pharmacutical developing DsiRNAs (Tekmira, Alnylam, ISIS, and Dicerna), all racing to 
develop the first DsiRNA theraputic.  
Although DsiRNAs are being havily investigated there has only been one published paper 
regarding chemical modifications within DsiRNAs (Collingwood, et al., 2008), and is an 
area wide open for future research. In their 2008 paper, they generated a small library of 
DsiRNAs containing only 2’-O-Me and 2’-F modifications, in positions known to 
improve properties of siRNAs. This is an opportunity to apply chemical modification 
patterns compatable with siRNAs and apply them to DsiRNAS to help improve upon the 
theraputic limitations of siRNAs and further optamize DsiRNAs. One interesting avenue 
to explore would be the dicer cleavage region itself, this region was completely avoided 
in the Collingwood (2008) paper due to the fear of dicer not cleaving the DsiRNA into a 
mature siRNA product. I would like to design DsiRNA with cleavable and non-cleable 
chemical modifications within and around the dicer cleavage region. This provides an 
exciting opportunity to explore the molecular function of the RNAi pathway, as it has 
been shown that siRNAs containing non-cleavable modifications around the argonaute 
cleavage region will still continue RNAi and supress mRNAs (Efthymiou, et al., 2012). 
By placing chemical modifications within the dicer cleavage region our understanding of 
the RNAi pathway could be further refined.  
There are many exciting opporunities worth further investaion. Including, determining 
potency by calculating IC50 values, investigating the exact molecular effects within the 
RNAi pathway, improving the therapeutic features of these siRNAs by combining more 
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Appendix Figure 2 - Sample picture of a standard oligonucleotide test gel. 
20% denaturing polyacrylamide gel was run in 0.5X TBE buffer. The gel was loaded with 0.5 OD units of 
oligonucleotide with denaturing loading solution for a total volume of 20 μL, the gel was ran for 16 hours at 80V. The 
gel was stained in a 3X solution of GelRed (Biotium) for 30 minutes while being gently stirred on a shaker. Finally 
RNA integrity was visualized via Fluorchem SP (Fisher Scientific). This gel displays pure and degraded 
oligonucleotides and most lanes needed further gel purification before use. 
 
 
Appendix Figure 3 - Sample picture of a successful RNA preparation. 
RNA was extracted using TRIzol reagent and visualized by running 5 μg of total RNA in a 1X agarose gel 
electrophoresis (60V for 45 minutes). The gel was stained in a 3X solution of GelRed (Biotium) for 30 minutes while 
being gently stirred on a shaker. Finally RNA integrity was visualized via Fluorchem SP (Fisher Scientific). Top band 
corresponds to mammalian 28s rRNA, middle band corresponds to mammalian 18s rRNA, lowest band corresponds to 




Appendix Figure 4 - High sensitivity standard curve of human IFN-α.  
Assay range 12.5 – 500 pg/ml. Standard curve constructed by plotting the optical densities (OD) of standards using 




























































Appendix Figure 6- 1H NMR of Synthesized Compounds. 
 
 

























Proton NMR Spectrum of Compound 5. 1H-NMR spectrum observed in CDCl3 at 400 MHz.  
